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ABSTRACT 
 
ANNE MOBLEY BUTLER: The cancer burden and patterns of erythropoiesis-stimulating  
agent use among end-stage renal disease patients on hemodialysis  
(Under the direction of M. Alan Brookhart) 
 
Patients with end-stage renal disease (ESRD) receiving dialysis have been reported to 
have increased risk of cancer. Yet, contemporary cancer burden estimates in this population are 
sparse, and estimates that account for the high competing risk of death in this population are non-
existent. In addition, erythropoiesis-stimulating agents (ESAs) and blood transfusion are 
commonly used to treat anemia in both ESRD and cancer, however, anemia treatment patterns 
have not been described among ESRD patients undergoing hemodialysis with concurrent cancer, 
especially in the recent era of ESA-related safety concerns. 
Using data from Medicare’s ESRD program, we conducted a retrospective cohort study 
of hemodialysis patients to describe trends in overall and site-specific cancer incidence rates 
(1996-2009). We estimated the 5-year cumulative incidence of cancer since dialysis initiation, 
using competing risk methods. Among hemodialysis patients with incident cancer, we used 
multivariable generalized linear models to estimate temporal trends in ESA use, epoetin alfa 
(EPO) dose, transfusion use, and resulting hemoglobin levels (2000-2010). 
We observed a constant rate of incident cancers for all sites combined, but identified 
increasing and decreasing rates for some common site-specific cancers. The 5-year cumulative 
incidence of any cancer was substantially lower in the analysis that did not censor deaths 
compared to the analysis that censored deaths (9.48% vs. 13.86%). Accounting for case-mix 
characteristics and the competing risk of death, the 5-year cumulative incidence of any cancer 
varied by demographic and clinical characteristics. 
Among hemodialysis patients with incident cancer, ESA use was extremely high and 
constant whereas transfusion use became increasingly frequent. EPO dose and hemoglobin 
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 values increased and then declined. Patients with hematological malignancies or patients who 
received chemotherapy had higher ESA use, EPO dose, and transfusion use as well as lower 
hemoglobin levels.  
Our results suggest a high burden of cancer in the dialysis population, with varying 
patterns of cancer incidence across subgroups. Despite ESA-related safety concerns, ESA use 
remained extremely common and remarkably constant among hemodialysis patients with cancer 
between 2000 and 2010. Transfusions have increased in frequency. These results warrant 
additional research to examine the risk-benefit profile of ESA use in the dialysis population with 
cancer. 
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 CHAPTER I.  STATEMENT OF SPECIFIC AIMS 
Patients with end-stage renal disease (ESRD) suffer almost universally from anemia because 
they produce insufficient amounts of endogenous erythropoietin to maintain hematocrit levels. Anemia is 
also a common complication in cancer patients undergoing chemotherapy. In the last two decades, 
erythropoiesis-stimulating agents (ESA) therapy has been widely used for anemia management in ESRD 
patients and cancer patients to reduce the need for red blood cell (RBC) transfusions and to alleviate 
anemia-related symptoms. In the last two decades, ESAs have had the highest sales worldwide of any 
biologic medication (1). Of $2.8 billion spent in 2010 on injectables for U.S. dialysis patients, ESAs 
accounted for 67%, or $1.9 billion (2). Beginning in 2003, eight randomized clinical trials in cancer 
patients reported increased risk of tumor progression and/or death among cancer patients treated with 
ESA therapy (3-11). Simultaneously, reports were published of increased risk of death and serious 
cardiovascular events in patients with chronic kidney disease (CKD). Over the next five years, 
subsequent United States Food and Drug Administration (FDA) black-box warnings, reimbursement 
changes, and revised anemia management guidelines were issued. Yet, it still remains unclear whether 
ESAs affect tumor progression or survival in cancer patients. The most recent meta-analysis of 60 
experimental studies of more than 15,000 cancer patients failed to demonstrate any significant effect of 
ESAs on survival or disease progression (12). Current management of anemia in dialysis patients with 
cancer has become challenging due to the absence of formal guidelines for providers regarding 
appropriate usage of ESA therapy in this population. The United States recommendation for CKD patients 
on dialysis receiving ESAs is to initiate treatment when the Hgb level is less than 10 g/dL and to 
individualize dosing and use the lowest dose of ESA sufficient to reduce the need for RBC transfusions 
(13), whereas the ESA indication for cancer patients is for treatment of anemia due to concomitant 
myelosuppressive chemotherapy (14). While the FDA limits ESA treatment among cancer patients to 
those receiving chemotherapy for palliative intent, the short expected lifespan of the average patient on 
dialysis (2) is likely associated with major variability in utilization practices in this population. 
Knowledge is limited about the cancer incidence in the dialysis population as well as patterns of 
ESA utilization in dialysis patients with cancer. Despite reports of increased risk of many cancers in the 
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 dialysis population (15-17), the cancer burden has not been sufficiently characterized in ESRD patients 
on dialysis. Existing estimates of cancer incidence in the ESRD population are outdated, primarily 
focused on overall cancer or limited cancer types, determined from small, selective groups of dialysis 
patients, based on data (e.g., cancer diagnoses and cause of death) ascertained from sources of 
questionable reliability, and failed to account for competing risks of death (15, 16, 18-39). Competing risk 
methods are necessary to avoid the potentially large bias due to a large proportion of patients who 
experience the competing risk of death prior to receiving a cancer diagnosis (i.e., the event of interest) 
(40-43). In addition, the impact of recent safety reports, FDA black-box warnings, reimbursement 
changes, and revised anemia management guidelines on ESA utilization patterns in dialysis patients with 
cancer is unknown. ESA therapy use declined among CKD patients (44) and cancer patients (45, 46) 
after these events. However, information is limited about patterns of ESA therapy utilization in dialysis 
patients with cancer.  
The objectives of this dissertation are to describe the cancer burden among ESRD patients on 
hemodialysis and to examine patterns of ESA utilization among ESRD patients on hemodialysis with 
cancer. The analyses utilized data from the USRDS, a national registry including all patients in Medicare’s 
ESRD program with detailed demographic and clinical information at dialysis therapy initiation, as well as 
medication usage, diagnoses, and procedures from hospitalizations and outpatient visits after 
hemodialysis therapy initiation. The study population included almost half a million adults with ESRD who 
received dialysis between 1995 and 2010.  
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 Aim 1. To characterize the overall and site-specific cancer burden among ESRD patients without cancer 
at hemodialysis initiation, across subgroups (e.g., by age, gender, race, ethnicity, primary cause of renal 
disease, kidney transplant evaluation, and era of dialysis initiation). 
 
Aim 1a. To estimate the cumulative incidence of cancer, treating death as a censoring event. 
 
Aim 1b. To estimate the cumulative incidence of cancer, treating death as a competing event. 
 
Aim 1c. To describe trends in cancer incidence using annual incidence rates adjusted for case-
mix characteristics.  
 
Hypothesis – Specific Aim 1. The cumulative incidence of cancer will be lower after accounting for the 
competing risk of death. The cumulative incidence and incidence rates will vary across subgroups, with 
higher cancer incidence among patients with older age, white race, kidney transplant evaluation, and 
longer time since dialysis initiation. 
 
Rationale – Specific Aim 1. Prior studies have demonstrated the increased risk of cancer in the dialysis 
population compared to the general population, under the hypothetical assumption of no competing risk of 
death. However, death is a common event in the dialysis population, and it precludes a cancer diagnosis. 
Competing risk methods are necessary to avoid the potentially large bias due to a large proportion of 
patients who experience the competing risk of death prior to receiving a cancer diagnosis (i.e., the event 
of interest). Estimation of the cumulative incidence of cancer, accounting for the competing risk of death, 
will quantify the real-world probability of a dialysis patient to develop cancer. The descriptive analysis of 
cancer incidence rates will vary by patient characteristics. 
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 Aim 2. To examine temporal trends in anemia therapy (2000-2010) in ESRD patients diagnosed with 
cancer after hemodialysis initiation, for a time period before, during, and after negative safety reports, 
product labeling changes, black box advisories, revised anemia management guidelines, and 
reimbursement changes. 
Aim 2a. To describe temporal trends in ESA therapy use among dialysis patients with cancer, by 
cancer site, receipt of chemotherapy, and other demographic and clinical characteristics relevant 
to the dialysis population.  
Aim 2b. To describe temporal trends in mean epoetin alfa (EPO) therapy dose among dialysis 
patients with cancer, by cancer site, receipt of chemotherapy, and other demographic and clinical 
characteristics relevant to the dialysis population.  
Aim 2c. To describe temporal trends in RBC transfusions among dialysis patients with cancer, by 
cancer site, receipt of ESA therapy, receipt of chemotherapy, and other demographic and clinical 
characteristics relevant to the dialysis population.  
Aim 2d. To describe temporal trends in mean Hgb levels among dialysis patients with cancer, by 
cancer site, receipt of ESA therapy, receipt of chemotherapy, and other demographic and clinical 
characteristics relevant to the dialysis population.  
 
 
Hypothesis – Specific Aim 2. The emergence of safety concerns and the subsequent changes in 
product labeling, reimbursement and clinical practice guidelines that occurred between 2003 and 2008 
will influence health care provider practices for dialysis patients with cancer. Specifically, post-FDA-
mandated labeling changes in dialysis patients with cancer will be characterized by a lower proportion of 
ESA therapy utilization, lower mean EPO dose, higher proportion of RBC transfusion, and lower mean 
Hgb values. Results will vary by cancer type and treatment, where patients with hematological 
malignancies and patients who undergo chemotherapy will be more likely to use ESA therapy, receive a 
higher EPO dose, receive RBC transfusions, and have lower Hgb values.   
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Rationale – Specific Aim 2. Anemia management patterns have been reported to have changed 
markedly in the years before and after the 2007 FDA black-box warning in the dialysis population and the 
cancer population. Anemia management patterns have not been described in the dialysis population with 
cancer. Recent reports about the dialysis population and the cancer population suggest declines in ESA 
therapy use, ESA dose, RBC transfusions, and hemoglobin levels. Changes in product labeling, 
reimbursement and clinical practice guidelines will likely have a similar but lesser impact on anemia 
management practices and Hgb levels in the ESRD population with cancer because of higher severity of 
illness. 
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 CHAPTER II.  REVIEW OF LITERATURE 
A. Overview of Chronic Kidney Disease (CKD) and End-stage Renal Disease (ESRD) 
1. Anatomy of the kidney 
The kidneys are a pair of small, bean-shaped organs located on each side of the vertebral 
column. Each kidney is approximately 11 to 12 cm long and weighs 115 to 170 g (47). The primary 
functions of the kidneys include filtering wastes from the blood, balancing the body's fluid content, and 
regulating blood pressure and RBC production. Healthy kidneys filter approximately 180 liters of largely 
protein-free plasma daily (48). A rich blood supply is delivered by the paired renal arteries, travels through 
the microvasculature, and drains into the paired renal veins. As the kidney filters blood it subsequently 
produces urine, a fluid containing toxic substances and waste products. Urine collects in the renal pelvis, 
exits the kidney through ureters, and flows to the urinary bladder (Figure 1).  
 
Figure 1. Diagram of the cut surface of a bisected kidney, depicting important anatomic structures 
 
Adapted from Nielsen et al. (2012) (47) 
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 Nephrons are the basic functional unit of the kidney. Each human kidney contains approximately 
one million nephrons which are established during prenatal development. After birth, new nephrons cannot 
be developed and lost nephrons cannot be replaced. The essential components of the nephron include a) 
the renal corpuscle, comprised of the glomerulus and Bowman’s capsule, and b) the renal tubule, 
comprised of the proximal tubule (i.e., convoluted part and straight part), the intermediate tubule (i.e., 
descending and ascending thin limbs of Henle’s loop) and the distal tubule (i.e., thick ascending limb of 
Henle’s loop and convoluted part). The glomeruli, proximal tubules and distal tubules are situated in the 
cortex, whereas the loops of Henle and the collecting ducts extend down through the medulla. Nephrons 
have either short or long loops of Henle, where the length of the loop of Henle is generally related to the 
position of the parent renal corpuscle in the cortex. Cortical nephrons have short loops that turn back in the 
outer medulla or even in the cortex. Juxtamedullary nephrons have long loops that turn back at successive 
levels of the inner medulla. Cortical nephrons and juxtamedullary nephrons represent approximately 85% 
and 15%, respectively, of the nephrons in the kidney. 
 
2. Physiology of the kidney 
The kidneys filter blood through three main processes: a) glomerular filtration filters blood to 
produce an ultrafiltrate of plasma; b) tubular secretion removes substances from the blood and secretes 
them into the filtrate; and c) tubular reabsorption returns substances to the blood.  
Glomerular filtration. The first fundamental step in urine formation is glomerular filtration which is the 
separation of blood into two components: filtered blood and an ultrafiltrate of plasma. As blood flows from 
the afferent arteriole into the glomerulus under high pressure, the glomerular capillary walls function as a 
filter that allows the passage of small molecules into the encircling glomerular capsule (i.e., Bowman’s 
capsule) while molecules the size of albumin or larger remain in the blood. The filtered fluid is called 
ultrafiltrate and includes water, small proteins, salts (Na+, Cl-, K+, H+), glucose, nitrogenous waste products 
such as urea and other metabolic waste products and drug metabolites. Filtration is determined principally 
by the molecular size and shape of the solute and, to a much lesser extent, by its charge (48). The remaining 
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 blood exits the glomerulus through the efferent arteriole and the ultrafiltrate exits the glomerular capsule 
into the proximal convoluted tubule.  
Tubular secretion. The second fundamental step in urine formation is tubular secretion which is the 
process that removes substances from the blood and secretes them into the filtrate. Secreted substances 
include H+, K+, NH4+ (i.e., ammonium ion), creatinine, urea, and various other substances. Secretion 
occurs in portions of the proximal convoluted tubule, the distal convoluted tubule and the collecting duct. 
 
Tubular reabsorption. The third fundamental step in urine formation is tubular reabsorption which 
increases the concentration of the glomerular filtrate by reabsorbing the glomerular filtrate back into the 
blood. As the glomerular filtrate flows through the proximal tubule, nearly all of the filtered water and 
solutes (Na+, Cl-, K+, Ca2+, Mg2+, HCO3+, glucose, amino acids, retinol-binding protein, α- and β-
microglobulins, calcium, phosphate, urea) are reabsorbed and transferred back into the peritubular 
capillaries that surround the tubule. The proximal tubule is conducive to reabsorption because of the large 
absorptive area of epithelial cells with microvilli on their apical surface; the basolateral membrane with 
folds that similarly enhance surface area; and the relatively leaky tight junctions between adjacent cells. 
The amounts of water and ions that are reabsorbed into the blood are regulated so that blood volume, 
pressure and ion concentration are maintained within required levels for homeostasis. Solute transport 
across cell membranes occurs via passive or active mechanisms. Passive transport is simple diffusion 
that occurs down an electrochemical gradient and does not require a direct energy source. Active 
transport occurs when an ion is moved directly against an electrochemical gradient and requires a source 
of energy.  
 
3. Measures of renal function 
The glomerular filtration rate (GFR) is the best overall index of renal function in health and 
disease, and provides an excellent measure of the filtering capacity of the kidneys. The total kidney GFR 
is equal to the sum of the filtration rates in each of the functioning nephrons. Thus, the total GFR can be 
used as an index of functioning renal mass (49). The definition and staging of CKD depends, in part, on 
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 the assessment of GFR. A low or decreasing GFR is a hallmark of CKD. As GFR declines, patient 
complications are manifested first by high blood pressure and abnormalities in laboratory tests and then 
by symptoms and abnormalities in physical examination. In general, the severity of complications worsens 
as levels of GFR declines. The most significant complications are high blood pressure, anemia, 
malnutrition, bone disease, neuropathy, and decreased overall functioning and well-being. At very low 
levels of GFR, these complications are common and collectively known as “uremia” or the “uremic 
syndrome (50).”  
Direct measure of GFR is an impracticality for clinical practice, therefore kidney function is routinely 
assessed using estimates of GFR (eGFR). Prediction equations such as the Modification of Diet in Renal 
Disease (MDRD) estimating equation (51), the Chronic Kidney Disease Epidemiology Collaboration (CKD-
EPI) equation (52) and the Cockcroft-Gault equation (53) commonly used to estimate GFR in adults factor 
in the serum creatinine concentration as well as age, gender and race. The most common method used to 
estimate renal function is the simplified four-variable Modification of Diet in Renal Disease (MDRD) 
equation, where GFR (mL/min/1.73 m2) = 186 * [serum creatinine level]-1.154 * [age]-0.203 * [0.742 if patient is 
female] * [1.212 if patient is black]. This equation was derived using data from 1,628 patients enrolled in 
the baseline period of the MDRD study, in whom GFR was measured directly with the use of urinary 
clearance of injected iodine-125-iothalamate (51). The more recently developed CKD-EPI equation 
performs better than the MDRD equation, especially at higher GFR, with less bias, improved precision, and 
greater accuracy. This equation was developed using an equation development data set of 8,254 
participants from 10 studies, a validation data set of 3,896 participants from 16 studies and prevalence 
estimates based on 16,032 National Health and Nutrition Examination Survey (NHANES) participants. The 
CKD-EPI equation is expressed as GFR (mL/min/1.73 m2) = 141 * min[serum creatinine level/Ƙ, 1]α * 
max[serum creatinine level/Ƙ, 1]-1.209 * [0.993]age * [1.018 if patient is female] * [1.159 if patient is black], 
where Ƙ is 0.7 for females and 0.9 for males, α is -0.329 for females and -0.411 for males (52).  
 
4. Definitions of CKD and ESRD 
CKD is defined as the presence for three or more months of impaired renal function across a 
continuum of renal injury from isolated anatomic, radiographic, biomarker, and urinary abnormalities to 
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 decreased GFR, irrespective of the primary cause of the renal injury (50). The National Kidney Foundation 
classification defines five stages of CKD by increasing degree of impaired kidney function, as measured by 
GFR (Table 1) (50). CKD is a nonspecific diagnosis that describes the presence and degree of structural 
and functional abnormalities of the kidney, thus the complete clinical diagnosis should include both the 
stage and primary cause of kidney disease (54). The abnormalities used to define CKD are 1) proteinuria 
(i.e., increased urinary excretion of albumin, other specific proteins, or total protein); 2) an abnormal urinary 
sediment as evidenced by the presence of RBCs, RBC casts, white blood cells, white blood cell casts, 
tubular cells, cellular casts, granular casts, oval fat bodies, fatty casts, or free fat; and 3) abnormal findings 
on imaging tests, including ultrasound, intravenous pyelogram, computer tomography, magnetic resonance 
imaging, and nuclear scans (54). The specific types of protein, such as albumin or low molecular weight 
globulins, that are excreted through urine depend on the type of kidney disease. For example, albuminuria 
(i.e., increased excretion of albumin) is a sensitive marker for CKD due to diabetes, glomerular disease, 
and hypertension. Increased excretion of low molecular weight globulins is a sensitive marker for some 
types of tubulointerstitial disease (50).  
 
Table 1. Stages of chronic kidney disease (age ≥20 years) 
Stage Description 
GFR 
 mL/min/1.73 m2 
1 Kidney damage with normal or increased GFR* ≥ 90 
2 Kidney damage with mild decreased GFR* 60-89 
3 Moderate decreased GFR 30-59 
4 Severe decreased GFR 15-29 
5 Kidney failure/ESRD < 15 
Adapted from KDOQI clinical practice guidelines for chronic kidney disease (2002) (50).  An estimated GFR 
above 60 mL/min/1.73 m2, in the absence of other anatomic, radiographic, or urinary abnormalities is not 
classified as CKD.  
 
 
End-stage renal disease (ESRD) is the final stage of CKD that occurs when renal function is 
insufficient to sustain life and renal replacement therapy (RRT), such as hemodialysis, peritoneal dialysis, 
or renal transplantation, is necessary for survival. ESRD is a syndrome characterized by hypertension, 
anemia, renal/metabolic bone disease, nutritional impairment, neuropathy, impaired quality of life, and 
reduced life expectancy (55).  
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 5. Pathogenesis of ESRD 
The progressive nature of renal disease has been characterized as a final common pathway of 
mechanisms, independent of the primary cause of nephropathy (56). Thus, CKD is a generic term for all 
of the clinical conditions with differing pathogenesis and widely varying pathologic characteristics that 
lead to the same pattern of chemical and functional derangements in the kidney which can eventually 
lead to renal failure (57).  
The central tenets of the common pathway theory state that CKD progression occurs through 
focal nephron loss and that the adaptive responses of surviving nephrons, although initially serving to 
increase single-nephron GFR and offset the overall loss in clearance, ultimately prove detrimental to the 
kidney. As the number of functional nephrons decreases, each residual nephron must perform a greater 
fraction of total renal function. In order to maintain balance of any specific solute and avoid retention of 
body fluid, the quantity excreted by each nephron must increase as the total population of functioning 
nephrons decreases. As kidney damage progresses, the remaining nephrons compensate for the 
reduction in nephron mass by increasing the single nephron filtration rate, and this hyperfiltration 
promotes further kidney injury. Raised glomerular hydraulic pressure (glomerular hypertension) appears 
to be the major effector of glomerular injury following renal mass reduction. Over time, glomerulosclerosis 
and tubular atrophy further reduce nephron number, fueling a self-perpetuating cycle of nephron 
destruction culminating in uremia (56, 57).  
After GFR falls to a critical threshold (i.e., approximately less than 50% of normal renal function), 
a progressive further loss of function ensues which leads to proteinuria, systemic hypertension, 
glomerulosclerosis, and eventual renal failure. This phenomenon has been observed in rats after partial 
ablation of renal mass as well as humans with diverse renal diseases, including individuals born with 
greatly reduced nephron number (i.e., congenital oligomeganephronia). In rats, a maximal increase of 
approximately 50% of GFR of a single kidney was reported at 8 days after uninephrectomy and a 300% 
increase in GFR of the remnant kidney was observed at 16 days after 5/6 nephrectomy (58). In humans, 
the effects of nephron loss on the physiology of the remnant kidney have been studied mainly in healthy 
individuals undergoing donor nephrectomy for kidney transplantation. A meta-analysis of data from 48 
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 studies that included 2,988 living human kidney donors estimated that single-kidney GFR (and therefore 
also the average single-nephron GFR) increased by 30% to 40% after uninephrectomy (59, 60). 
 
6. Risk factors for progression to ESRD 
Risk factors for CKD can be separated into susceptibility, initiation, and progression factors. 
Susceptibility factors predispose to CKD, initiation factors trigger kidney damage, and progression factors 
contribute to progression of kidney damage after CKD has developed. This section focuses on 
progression to ESRD. Briefly, kidney function progressively declines in most patients with CKD after 
sufficient damage has occurred to lower the GFR, regardless of the cause of the initial renal injury. While 
the rate of GFR decline is often relatively constant over time in an individual patient, the rate of GFR 
decline is highly variable among patients, ranging from slowly progressive over decades to rapidly 
progressive over months. The high variability in the rate of progression of CKD between individuals 
suggests that risk factors exist that may influence the course of the renal disease. The major risk factors 
for progression to ESRD include age, race/ethnicity, diabetes, hypertension, glomerulonephritis, elevated 
serum creatinine, obesity, smoking, and use of nonsteroidal anti-inflammatory drugs (61-63). 
 
7. Treatment modalities: hemodialysis, peritoneal dialysis, kidney transplantation 
RRT options for ESRD patients include hemodialysis, peritoneal dialysis and renal 
transplantation. Renal transplantation is the preferred method for treatment because it is associated with 
longer survival, less hospitalizations, better quality of life, and lower costs compared with dialysis (2, 64). 
Preemptive transplantation, which is transplantation performed before dialysis is ever initiated, is 
associated with better outcomes than transplantation following dialysis (65). Change in modality is much 
more common for peritoneal dialysis to hemodialysis than from hemodialysis to peritoneal dialysis, and 
that change in treatment from peritoneal dialysis to hemodialysis is associated with an increased risk of 
hospitalization and mortality (66). The optimal time for initiation of RRT varies by modality, clinical 
characteristics and sociodemographic characteristics. Patients who receive a preemptive transplant or 
initiate peritoneal dialysis begin RRT therapy at higher mean levels of GFR than patients who initiate 
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 hemodialysis. Dialysis is initiated at higher mean levels of GFR among patients who are older, or who 
have diabetes, cardiovascular disease, or other comorbid conditions (2, 50). A detailed description of all 
RRT modalities is presented below. 
Hemodialysis. The purpose of hemodialysis is to deliver blood reliably from the patient to the dialyzer, to 
enable an efficient removal of uremic toxins and fluid, and to deliver the cleared blood back to the patient. 
Vascular access is a necessary step prior to dialysis. The main components of the dialysis system are the 
extracorporeal blood circuit, the dialyzer, the dialysis machine, and the water purification system. The 
dialysis machine delivers dialysis fluid with the intended flow rate, temperature, and chemical composition. 
The dialysis machine has monitoring and safety systems for air, blood, conductivity, and pressure; blood 
and dialysate pumps; a heating system; a dialysate mixing and degassing unit; and an ultrafiltrate balancing 
system. The role of the water purification system is to produce water for dialysis that complies with set 
chemical and microbiologic standards (67). Thus, hemodialysis replaces the work of the damaged kidneys 
by using an artificial kidney machine to filter blood. Hemodialysis is conventionally delivered in three 
treatment sessions per week, except for occasional patients with substantial residual renal function that opt 
for two treatment sessions per week. Typical treatment lengths are 3 to 4 hours per session (67). 
Hemodialysis is almost always performed in dialysis facilities and rarely performed at home. Sixty percent 
of dialysis patients are treated in units owned by Fresenius or DaVita, and the remainder are treated in 
units owned by Dialysis Clinic, Inc., other small dialysis organizations, or hospital-based facilities (2). 
Peritoneal dialysis. The purpose of peritoneal dialysis is to provide a continuous mode of removal of small 
solutes and excess body water, thus maintaining relatively stable blood chemistry and body hydration 
status. The peritoneal cavity, which is the largest serosal space in the body, is used as a container for 2 
to 2.5 liters of sterile, usually glucose-containing dialysis fluid. The peritoneal membrane acts as an 
endogenous dialyzing membrane through which waste products diffuse to the dialysate and excess body 
fluid is removed by osmosis. Ultrafiltration is induced in the dialysis fluid using glucose or another osmotic 
agent. The dialysis fluid is provided in plastic bags and is exchanged four or five times daily through a 
permanent peritoneal indwelling catheter. A catheter is necessary to provide obstruction-free access to 
the peritoneum and can be inserted surgically at the patient’s bedside by an experienced nephrologist or 
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 a surgeon or through a laparoscopic insertion (68). Peritoneal dialysis is a home-based therapy, and most 
patients are trained to do the bag exchanges themselves. Peritoneal dialysis is usually provided 24 hours 
a day and 7 days a week in the form of continuous ambulatory peritoneal dialysis (69).  
 
Renal transplant. Transplantation is performed to replace the damaged kidneys with a functional kidney. 
Only one donated kidney is necessary to resume renal function. In preparation for transplantation, 
patients undergo a comprehensive evaluation of medical, surgical, and psychosocial histories (70-72). 
The availability of more potent immunosuppression and improvements in human leukocyte antigen (HLA) 
typing and crossmatching have made it feasible for immunologically high-risk patients to be considered 
candidates for transplantation (73). Three sources of kidneys for transplantation in order of most to least 
frequent are: donation before cardiac death donors, donation after cardiac death cadaveric donors, and 
live donors. Preservation of deceased donor organs is crucial to allow time for matching, sharing of 
organs, and preparation of the recipient. Organs are preserved by cold storage (kept in crushed ice after 
flushing with preservation solution) or by machine-driven pulsatile perfusion (74). The renal 
transplantation procedure involves general anesthesia before surgery. The kidney is placed into the iliac 
fossa. The external iliac artery and vein are mobilized. Surrounding lymphatic vessels are ligated and 
divided. End-to-side anastomoses are performed between the renal vein and the external iliac vein, 
followed by the renal artery and the external iliac artery. The ureter is implanted into the bladder (74, 75). 
Blood is then able to flow through the transplanted kidney, and the kidney should begin to filter and 
remove wastes and to produce urine. Kidney transplant surgery takes about three hours. After transplant, 
immunosuppressive medications are administered to prevent organ rejection (73). Major postoperative 
complications are rare. Surveillance of laboratory testing in the kidney transplant recipient is a routine and 
critical part of post-transplant management because early detection and treatment of graft dysfunction is 
crucial for preservation of allograft function.  
 
8. Clinical and preventive care of ESRD patients 
Given the risks and associated complications of infections in ESRD patients on dialysis, 
strategies to effectively improve overall care and prevent complications are of paramount importance. 
14 
 
 Although the majority of national guidelines emphasize the importance of timely preparation for dialysis 
and clinical management of dialysis recipients, several measures fall far short of recommended 
guidelines. A number of clinical indicators and preventive care measures are discussed below, including 
early referral to a nephrologist, vascular access, dialysis adequacy, diabetic management, and 
vaccinations. Anemia management is summarized later in the chapter. 
 
Early referral to a nephrologist. Adequate preparation for initiation of dialysis is important for patients with 
progressive CKD approaching renal failure. The Kidney Disease Outcomes Quality Initiative (KDOQI) 
Clinical Practice Guidelines for CKD recommend that CKD patients with GFR less than 30 mL/min/1.73 
m2 should be referred to a nephrologist (50) as patients referred earlier to nephrology services have 
reduced mortality, hospitalization and vascular access infections (2, 76, 77). Improved prognosis among 
patients with early referral appears to be independent of differences in traditional cardiovascular risk 
factors and instead related to careful management during the transition to ESRD. Specific explanations 
include informed selection of RRT, placement and maturation of vascular access, workup for kidney 
transplantation, counseling for coping with the psychosocial effects of starting RRT, and arrangement of 
family and work commitments (77, 78). Effective preparation for RRT requires input from multiple staff 
disciplines (e.g., medical, nursing, pharmacy, dietetics, psychology and social work) and is best delivered 
in a multidisciplinary clinic (78). In 2010, 25.4% of ESRD patients in the United States had seen a 
nephrologist for at least 12 months prior to RRT initiation (2). 
 
Vascular access. Functional vascular access is necessary for hemodialysis. Certain types of vascular 
access are associated with substantially higher risks of infectious morbidity and mortality. Several types of 
vascular access used in hemodialysis, listed in order of increasing risk of infection, are as follows: 
arteriovenous fistulas (AVFs) created from the patient’s own blood vessels; arteriovenous grafts 
constructed from synthetic materials; tunneled central venous catheters; and nontunneled central venous 
catheters (79, 80). Compared with AVFs, dialysis catheters are associated with a nearly two-fold 
increased risk for bacteremia or sepsis (81) and a more than two-fold increased risk for infection-related 
mortality (82). Guidelines from the KDOQI Clinical Practice Guidelines for Vascular Access (83) and the 
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 Fistula First initiative (84) recommend that catheter use be reduced and that more patients use an AVF. 
Despite this consensus, AVF utilization has historically been very low. In 2010, only 36% of incident 
hemodialysis patients in the United States had an AVF access either in use or maturing at the first 
outpatient dialysis treatment (2).  
Dialysis adequacy. Patients with renal failure require dialysis to remove uremic toxins from the blood 
because their damaged kidneys can no longer metabolize and secrete these toxins into the urine. Urea is 
only mildly toxic, but a high urea level indicates simultaneous retention of many other waste products that 
are more harmful and not as easily measured. Dialysis adequacy refers to the delivery of a dialysis dose 
that is sufficient to remove waste products such as urea from the blood and to ultimately promote an 
optimal long-term outcome (85). Poor dialysis adequacy has been associated with morbidity in 
hemodialysis patients at dialysis doses well below the current standard (86), however, the current 
standard seems appropriate (79, 87). The KDOQI Clinical Practice Guidelines for Vascular Access 
recommend that dialysis adequacy be assessed by monthly measurement of the delivered dose of 
dialysis (79). The delivered dose of dialysis is assessed by the removal of urea and expressed either by 
the urea reduction ratio (URR) or by the treatment index Kt/V. URR refers to the treatment-related 
reduction of serum urea concentration and is computed as follows: URR (%) = (1 - Ct/C0) x 100% where 
Ct is post-dialysis and C0 is predialysis serum urea concentration. URR correlates well with dialysis 
outcome and is an accepted method for assessment of dialysis adequacy (85). A minimum URR of 65% 
to 70% is recommended for adequate hemodialysis (79). Alternatively, the treatment index Kt/V is the 
most widely used parameter to assess dialysis dose. Kt/V is a dimensionless number representing urea 
volume cleared (K x t, in liters) divided by urea volume of distribution (V, in liters), where K is the dialyzer 
blood water urea clearance (liters per hour), t is dialysis session length (hours), and V is the distribution 
volume of urea (liters), which equates closely to total body water (85). A minimum Kt/V of 1.2 and 1.7 is 
recommended for adequate hemodialysis and peritoneal dialysis, respectively (79). A patient's URR or 
Kt/V can be increased either by increasing time on dialysis or increasing blood flow through the dialyzer. 
In 2010, 94.0% of hemodialysis patients achieved URR greater than or equal to 65% and 87.1% of 
peritoneal dialysis patients achieved a minimum Kt/V of 1.7  (2). 
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 Diabetic management. Diabetes is the most common cause of ESRD in the United States (2, 88). Among 
ESRD patients, diabetes is a strong risk factor for infections, cardiovascular disease, hospitalizations and 
mortality (2, 82). Glycemic control can be achieved with insulin or oral hypoglycemic agents, however, 
ESRD patients face therapeutic challenges such as prolongation of insulin half-life and accumulation of 
oral hypoglycemic agents that make self-monitoring of blood glucose concentration imperative (89). 
Additional therapeutic challenges in this population include hypertension, hypervolemia, malnutrition and 
bacterial infections (90). Microvascular (e.g., retinopathy and polyneuropathy), macrovascular (e.g., 
coronary heart disease, left ventricular hypertrophy, congestive heart failure, stroke and periperal artery 
occlusive disease) and mixed (e.g., diabetic foot) complications are common, thus patients should be 
monitored at regular intervals for timely detection (90). Comprehensive diabetic monitoring includes at 
least four glycosylated Hgb (A1c) tests, two fasting lipid profile tests, and one eye examination yearly. 
Although the rate of comprehensive monitoring among ESRD patients with diabetes has been increasing 
over time, between 2009-2010 only 17.2% of prevalent diabetic ESRD patients in the United States 
received all three types of recommended preventive care  (2).  
 
Vaccinations. Viral infections are a common cause of morbidity and mortality in ESRD patients, therefore 
the Centers for Disease Control and Prevention recommends that dialysis patients receive regular 
influenza, pneumococcal and hepatitis vaccinations. Although dialysis patients have lower response rates 
to vaccination compared with the general population, immunogenicity studies report development of 
protective antibody levels for the majority of influenza, pneumococcal and hepatitis B strains (91-94). 
Vaccine administration to dialysis patients has been reported to be a cost-effective approach for 
prevention of infections (95-97), however, recent reports of limited vaccine effectiveness raise concerns 
about vaccination policies in the ESRD population (98, 99). To date vaccination remains an underutilized 
prevention strategy in the ESRD population, with rates of vaccination far below the Healthy People 2020 
target of 90%. In 2009, rates of vaccinations in prevalent ESRD patients receiving hemodialysis were as 
follows: influenza (69%), pneumococcal pneumonia (30%), hepatitis B (28%). Rates should be interpreted 
with caution, as patients may be vaccinated through non-Medicare programs (2). 
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 B. Epidemiology of ESRD in the United States 
1. Incidence and prevalence of ESRD  
More than 114,000 new ESRD cases initiated RRT in 2010, for an adjusted ESRD incidence rate 
of 348 per million population. The rate of incident ESRD cases per million population has been relatively 
stable since 2000, and rose just 1.1% in 2009, to 355 cases per million population (adjusted for age, 
gender and race). The prevalence of ESRD has been steadily increasing. Nearly ten times more patients 
in the United States were treated for ESRD in 2009 compared to 1980. Since 2000, the adjusted rate of 
prevalent ESRD has increased nearly 23%. The annual rate of increase has remained between 1.9% and 
2.4% since 2003. Of more than 593,000 prevalent ESRD cases receiving RRT at the end of 2010, the 
distribution of treatment modalities were as follows: hemodialysis, 64.7%; renal transplantation, 30.2%; 
and peritoneal dialysis 5.0%. A total of 87,932 were on the renal transplant waiting list, which has a 
median wait time of 2.6 years (2). 
The incidence of ESRD varies considerably across patient subgroups (Table 2). ESRD incidence 
increases with age and is more common among men than women. In 2010, the incidence rate of ESRD 
was 3.4 times higher in blacks and 1.7 times higher in Native Americans compared to whites. Compared 
to the non-Hispanic population, the Hispanic population had an incidence rate 1.5 times higher. Similarly, 
the ESRD prevalence in 2010 was higher among minority groups: blacks, 5234 per million population 
(pmp); Hispanics, 2602 pmp; Native Americans, 2563 pmp; Asians, 2098 pmp; and whites, 1309 pmp. 
Rates of ESRD vary substantially by geography. The highest adjusted rates occur in the Ohio Valley, 
portions of Texas and California, and the southwestern states. 
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 Table 2. Incident and prevalent counts and adjusted rates of ESRD by age, gender, race and ethnicity, 
U.S., 2010* 
 Incidence Prevalence 
  
Number of 
patients 
Rate per 
million** 
Number of 
patients 
Rate per 
million** 
Age     
    20-44 13,404 127  98,008 937 
    45-64 43,663 579  261,445 3,395 
    65-74 27,029 1,365  119,751 6,062 
    75+ 28,640 1,771  93,202 5,862 
Gender     
    Male 64,905 440  328,529 2,166 
    Female 49,127 275  251,226 1,423 
Race     
    White 75,514 275 353,849 1,309 
    Black 31,686 923 186,482 5,234 
    Native 
American 1,389 465 7,958 2,563 
    Asian 5,443 387 31,466 2,098 
Ethnicity     
    Hispanic 15,273 501 85,062 2,602 
    Non-Hispanic 98,759 337 494,693 1,714 
*These data exclude patients with missing demographic information. 
**Adjusted for age, gender, race and ethnicity, as appropriate. 
 
 
In the United States, the three most common primary diagnoses for ESRD are diabetes, 
hypertension and glomerulonephritis (Table 3). Since 2000, the rate of incident ESRD caused by diabetes 
has remained quite stable (with the exception of an increase in 2006), the rate of incident ESRD due to 
hypertension has increased 9%, and the rate of incident ESRD due to glomerulonephritis has decreased 
23%. In 2010, the primary diagnoses of diabetes and hypertension were associated with 44% and 29% of 
incident ESRD patients, respectively (2).  
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 Table 3. Incident and prevalent counts and adjusted rates of ESRD by most common primary diagnoses, 
U.S., 2010 
 Incident ESRD Prevalent ESRD 
Primary Diagnosis 
Number of 
patients 
Rate per 
million*  
Number of 
patients 
Rate per 
million* 
Diabetes 50,305 151.7 219,568 655.1 
Hypertension 32,510 99.0 145,011 436.9 
Glomerulonephritis 7,290 22.7 84,318 262.2 
*Adjusted for age, gender, race and ethnicity.   
 
 
2. Kidney transplantation in the ESRD population  
In 2010, 16,843 kidney transplants were performed in patients ≥20 years in the United States. 
Among incident ESRD patients in 2009, 22% were added to the waiting list or received a transplant within 
one year of ESRD certification, a proportion remaining fairly stable over the past two decades. The 
median wait time for patients transplanted in 2010 was 2.6 years. The number of adult candidates on the 
kidney transplantation waiting list with certified kidney failure continues to increase, with a 6% increase in 
2010 to reach 75,807 patients on December 31 (2). Of patients listed on the transplant wait list in 2006, 
substantially more whites (21%) than blacks (9%) received a living donor transplant within three years. 
After three years, 47% of blacks and 31% of whites were still waiting for a transplant (100). 
 
3. Mortality in the ESRD population  
Mortality is exceptionally high in the ESRD population. The most common causes of death in 
United States prevalent dialysis patients between 2008 and 2010 were cardiovascular events (41.5%), 
infections (10.9%), withdrawal of dialysis (10.5%) and malignancy (3.7%). Survival probabilities for the 
2004 USRDS cohort of incident ESRD patients was 75% at one year, 50% at three years, and 34% at five 
years following dialysis initiation (100). Mortality is highest during the first year of dialysis. Specifically, 
mortality rates are lowest within the first month, peak in the second and third month, and slowly decline in 
months four through twelve to return to a similar rate as the first month (2, 101). For incident hemodialysis 
patients in 2009, all-cause mortality reached 435 deaths per 1,000 patient-years at risk in month two, then 
fell to 206 by month 12. Cardiovascular mortality peaked at 169 in month two, and decreased to 78. 
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 Infection-related mortality peaked in months two and three, at 40-43 deaths per 1,000 patient-years at 
risk. Hemodialysis and peritoneal dialysis patients have similar survival probabilities during the first year 
of treatment, although the risk of death appears to be higher for peritoneal dialysis in the second year 
(102). Prevalent death rates have been falling for a number of years, and mortality in the first year of 
dialysis has, since 2004, continued to decline, reaching rates which are the lowest in 30 years (2). 
 It is well-established that black ESRD patients on dialysis experience better survival compared to 
whites, despite the higher mortality rates in blacks versus whites in the general population and in earlier 
stages of CKD. Among 20 cohort studies from North America and Canada that examined black-white 
differences in all-cause mortality among ESRD patients on dialysis therapy, adjusted hazard ratio 
estimates comparing blacks to whites or non-blacks ranged between 0.4 and 1.0 (103-122). The wide 
variability in estimates of the black-white disparity in all-cause mortality is likely attributable to differences 
in the following study characteristics: time origin for analysis (range, 0 days to 1 year after dialysis 
initiation among incident ESRD patients), variable follow-up period (range, 90 days to 14.8 years), 
inclusion of prevalent dialysis users (n=4 studies), inclusion of peritoneal dialysis users (n=16 studies), 
small sample of black patients (minimum = 45 blacks), population-specific prevalence of comorbidities 
including diabetes mellitus and hypertension, methods to account for competing events (e.g., 
transplantation, change in dialysis modality, dialysis withdrawal), and availability of data on vascular 
access status, laboratory assessments, and provider characteristics. No meta-analyses have been 
conducted to date. However, the adjusted hazard ratio of 0.84 (95% CI, 0.83-0.84) reported by Kucirka et 
al. (106) likely represents the best estimate due to the large USRDS population (N=1,330,007), the large 
sample size of blacks (n=407,140), the time origin of ESRD onset, the long follow-up period (14.8 years), 
and exploration of subgroups (e.g., age is an effect modifier). 
 
4. Economic burden of ESRD 
The direct financial cost of care for the ESRD population is substantial. In 2009, national 
expenditure reached $42.5 billion, including $29 billion for Medicare spending and $13.5 billion for non-
Medicare spending. Although ESRD patients only account for 1.3% of Medicare patients, ESRD patients 
account for 8.1% of Medicare spending. Annual Medicare costs per patient were $82,285 for 
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 hemodialysis recipients, $61,588 for peritoneal dialysis recipients and $29,983 for transplant patients 
(100). These costs only partially capture the full economic burden of ESRD, which includes the costs of 
chronic disability, premature mortality, and diminished quality of life (55). 
 
 
C. Cancer in the ESRD population 
1. Cancer burden in the ESRD population 
Prevalence. In the USRDS data, information on history of cancer before dialysis initiation is ascertained 
on the Medical Evidence Report by a question about “malignant neoplasm/cancer in the last 10 years.” 
Studies commonly report cancer prevalence estimates from this data as baseline characteristics of the 
study population. For example, a recent study of incident hemodialysis patients reported a steady 
increase over the study period in cancer prevalence from 3.9% in 2002 to 4.7% in 2008 (123). In another 
study of ESRD patients who initiated hemodialysis between 1995 and 2009, estimates of cancer 
prevalence varied substantially by age and race: white patients 18-30 years (1.0%); white patients 31-50 
years (2.6%); white patients >50 years (8.4%); black patients 18-30 years (0.5%); black patients 31-50 
years (1.5%); and black patients >50 years (5.8%) (106). 
 
Incidence. The incidence of cancer is not well characterized in the dialysis population (17). Annual 
estimates of cancer incidence rates do not exist. Two studies that report standardized incidence ratios 
(SIRs) for overall and site-specific cancers in ESRD patients compared to the general population (Table 
4) do not directly report site-specific cancer incidence estimates, however, the data necessary for 
calculation of cancer incidence over the study periods (i.e., 1980-1994 (15) and 1982-2003 (16)) are 
presented in the publication tables.  
 
Mortality. According to the 2012 USRDS Annual Data Report, mortality was attributable to malignancy in 
5.0% of incident dialysis patients (i.e., first 180 days of dialysis) and 3.7% of prevalent dialysis patients in 
the period between 2008-2010 (2). Otherwise, mortality studies in dialysis patients primarily report on all-
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 cause or cardiovascular mortality, with very little focus on cancer mortality. One recent exception is the 
2010 study of U.S. hemodialysis patients that reported stable cancer-specific mortality rates between 
1995 and 2005. Crude first-year cancer-specific mortality rates for 1995 and 2005 were 13.8 and 15.2 
deaths per 1,000 patient-years, respectively (18). These rate estimates are limited by lack of covariate 
adjustment and highly inaccurate cause of death data from the Death Notification form (CMS-2726) (124, 
125).  
 
2. Epidemiologic studies of cancer risk in the ESRD population  
ESRD patients on dialysis have a modestly increased risk for many cancers compared to the 
general population (Table 4) (15-17, 23). A large, international, collaborative study (n=831,804) from three 
registry populations from the United States, Europe, and Australia/New Zealand with data from 1980-
1994 reported that ESRD patients on dialysis had an elevated risk of many cancer sites, including kidney 
(SIR=3.60 (95% CI, 3.45-3.76)), bladder (SIR=1.50 (95% CI, 1.42-1.57)), and thyroid and endocrine 
organs (SIR=2.28 (95% CI, 2.03-2.54)) compared to the background population (accounting for age, sex, 
race, country, and calendar time). Other sites with excess cancer risk included Kaposi’s sarcoma and 
tumors of the oral cavity, stomach, liver, lung and cervix (15). A more recent analysis of the Australia/New 
Zealand registry (n=24,926) included extended follow-up (1982-2003) and reported similar cancer site-
specific risk estimates as reported by Maisonneuve et al (16). A 2012 population-based case-control 
study among U.S. elderly adults (1,029,695 cancer cases and 99,610 controls) reported similar elevated 
risks for cancers of the stomach, small intestine, colon, liver, biliary tract, lung, cervix, and kidney, as well 
as multiple myeloma and chronic myeloid leukemia. No increase in risk was identified for cancers 
previously reported to have increased risk such as thyroid cancer, non-Hodgkin lymphoma (modest 
inverse association), Hodgkin lymphoma, and Kaposi sarcoma (23). These studies reported excess 
cancers in several organs for which viruses have been suspected as causative agents (e.g., hepatitis B 
and C/liver cancer; Epstein-Barr/lymphoma; HPV/ tongue, cervix, vagina, vulva, penis cancers) (15, 16, 
23).  
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Table 4. Published studies of cancer incidence in the dialysis population 
Data source & 
study population 
Years  N Cancer (N or %) Overall cancer 
relative risk (95% 
CI) 
Site-specific 
cancer (N) 
Site-specific cancer 
relative risk (95% CI) 
 
Maisonneuve et al (1999) 
Three national 
dialysis registries 
with cancer 
information 
 
Australia & NZ 
Europe 
U.S.  
1980-1994 831,804 
dialysis 
patients 
Pooled 
25,044 
 
 
 
 
 
By region 
500 
6,849 
17,695 
 Pooled 
1.18 (1.17-1.20) 
 
 
 
 
 
By region 
1.8 (1.7-2.0) 
1.1 (1.0-1.1) 
1.2 (1.2-1.2) 
Kidney (2,053) 
Bladder (1,646) 
Thyroid & other   
endocrine 
organs (314) 
 
3.60 (3.45-3.76)  
1.50 (1.42-1.57)  
2.28 (2.03-2.54)  
Vajdic et al. (2006) 
Population-based 
cohort of 
ANZDATA & 
Australian 
National Cancer 
Statistics 
Clearing House 
1982-2003 28,855 
dialysis 
patients 
1,136 
 
870, excluding cancers known 
to frequently cause ESRD 
(i.e., kidney, renal pelvis, 
myeloma, bladder, ureter, and 
other urinary organs) 
1.98 (1.88-2.09) 
 
1.35 (1.27-1.45) 
 
Lip (29)  
Tongue (12)  
Stomach (28)  
S. intestine (6)  
Liver (14)  
Lung (135)  
Cervix (13)  
Thyroid (38) 
 
Anal (2)  
Prostate (74) 
↑               
↑               
↑               
↑                
↑               
↑               
↑               
↑               
 
↓ 
↓              
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Shebl et al. (2012) 
Population-based 
case-control 
study among US 
elderly using 
SEER-Medicare 
data 
1992-2005 1,029,695 
cancer 
cases & 
99,610 
controls 
ESRD in: 
- 0.35% cancer cases 
 - 0.36% controls 
1.02 (0.91-1.14) 
 
 
Stomach (118) 
S. intestine (24) 
Colon (390) 
Liver (63) 
Biliary tract (27) 
Lung (661) 
Cervix (28) 
Multiple myeloma 
(92) 
Chronic myeloid 
leukemia (18) 
1.45 (1.16-1.81)  
1.92 (1.27-2.92)  
1.17 (1.00-1.36)  
1.53 (1.16-2.01)  
1.78 (1.20-2.65)  
1.17 (1.02-1.34)  
2.12 (1.39-3.23)  
1.77 (1.40-2.24)  
1.74 (1.08-2.80)  
 
↑ denotes increased incidence, where SIRs unavailable; ↓ denotes decreased incidence, where SIRs unavailable. 
 
  
Information on cancer incidence in dialysis patients by subgroups is sparse. Despite the 
recognized racial disparity in cancer incidence and the increased risk of many cancers among dialysis 
patients, no studies of dialysis patients have comprehensively investigated whether cancer risk differs 
between blacks and whites. Effect modification of cancer risk by race has been reported in a number of 
large studies of kidney transplant recipients, with a demonstrated decrease in risk for blacks relative to 
whites (126-129). Future studies are necessary to estimate black-white differences in risk of cancer (all 
sites and site-specific) among dialysis patients, accounting for differential rates of death. 
These studies have several limitations. Authors of the large, international study (15) note two 
major limitations that may have affected the cancer risk estimates. First, there was variable data quality 
across the three registry populations, in terms of completeness of the dialysis population and complete 
ascertainment of cancer diagnoses. Secondly, it is possible that some patients with prevalent cancers 
may not have been excluded from the analysis, despite the exclusion of patients with a cancer diagnosis 
that preceded dialysis or in whom cancer treatment was the cause of renal failure. Third, the 
Australia/New Zealand study of registry data (16) likely had the most complete ascertainment of dialysis 
patients and cancer outcomes, however, many of the cancer site-specific estimates are limited due to the 
relatively small study population (N = 28,855). Fourth, subgroup analyses have been limited. Lastly, none 
of these studies used competing risk methodology to account for the high annual mortality in the dialysis 
population.  
 
3. Cancer as a cause of CKD/ESRD 
Of 558,639 incident ESRD patients in the United States between 2005-2009, a small proportion 
of these patients had a malignancy-related primary cause of ESRD including multiple myeloma (n=5,700, 
1.0%), malignant renal tumor (n=2,191, 0.4%), malignant urinary tract tumor (n=727, 0.1%), lymphoma of 
kidneys (n=190, 0.0%), other immunoproliferative neoplasms (n=710, 0.1%) ((100)). Accordingly, Vajdic 
et al. separately examined the risk of cancers known to frequently cause ESRD (i.e., myeloma, kidney 
and urinary tract cancers), and did not include these cancers in the overall cancer rate (16).  
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 4. Pathogenesis and progression of cancer in the ESRD population 
The increased risks reported for several infection-related cancers (i.e., liver, stomach, and 
cervical cancers) could reflect immunodeficiency associated with ESRD. Chronic uremia leads to 
metabolic abnormalities that alter the immune response such that antigen-presenting cell function is 
impaired, lymphocyte survival is shortened, proliferation of T-cells is impaired, together with an increased 
suppressor T-cell activity, decreased helper T-cell (Th) activity, and increased Th1/Th2 ratio (130, 131). 
Nutritional abnormalities that are prevalent among ESRD patients, such as selenium deficiency, reduced 
glutathione peroxidase activity, and vitamin D deficiency (132-135) could also play a role in development 
of cancer, particularly for colon cancer (136-138). Erythropoietin, which is commonly used among ESRD 
patients for the treatment of anemia, may contribute to carcinogenesis via two proposed mechanisms: 
activation of EPO receptors that exist on the surface of the cancer cells, and EPO-induced angiogenesis 
that allows the tumor to grow and spread (1, 139). Excess cancer risk may also be due to an interaction 
of uremic and dialysis-induced immune dysfunction with established risk factors such as UV radiation (lip 
cancer), tobacco (lip, lung, and cervical cancer), or alcohol (liver cancer) (16).  
 
5. Cancer screening in the ESRD population 
Although evidence suggests that dialysis patients have increased risk for cancer, screening for 
cancer in ESRD patients remains controversial due to the exceptionally high mortality in this population 
(2, 140, 141). Population-based estimates suggest that cancer screening occurs less frequently in dialysis 
patients compared to the general population (142). Possible causes for lower screening rates include 
physician inattentiveness, physician fatalism about patient outcomes, poor patient adherence to testing 
procedures, and inadequate financial coverage for screening (142). The cost-effectiveness of cancer 
screening depends, in part, on the survival benefit and the cost of the screening test and treatment. Cost-
effectiveness analyses suggest that a general screening program in this population would be a relatively 
inefficient allocation of financial resources, and would add minimal days of life saved per person under 
the most optimistic assumptions (143-145). Despite lower rates of screening in the ESRD population, 
these patients are not more likely to present with later stage malignancies, with the exception of prostate 
cancer (146). This may be attributable to the higher frequency of healthcare visits or more intensive 
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 medical workups in patients who are on dialysis (146). ESRD patients undergo comprehensive evaluation 
of medical, surgical, and psychosocial histories to become a kidney transplant candidate (70-72). Patients 
with active or recent history of malignancy are generally contraindicated for immunosuppression, 
therefore they are advised to postpone or cancel further transplant evaluation (70). An individualized 
approach to cancer screening in dialysis patients is required and should be based on the patient’s cancer 
risk factors, expected survival, and transplant status (141). 
 
6. Cancer treatment in the ESRD population 
Cancer in a dialysis patient is generally treated as in the nondialysis patient with appropriate 
consideration of the renal clearance, dosing, and dialyzability of chemotherapeutic agents. Dialysis must 
often be precisely timed in conjunction with chemotherapy administration to avoid toxicity. The lack of 
clinical trials in this population precludes definitive recommendations. Therefore recommendations for 
treating dialysis patients with cancer can be made only when data on prognosis become available. 
Individualized treatment through collaboration of surgeons, oncologists, nephrologists, and dialysis units 
is vital. (141).  
 
D. Erythropoiesis-stimulating agent (ESA) therapy for anemia management 
1. Pathogenesis of anemia in ESRD patients   
Patients with ESRD suffer universally from anemia because they produce insufficient amounts of 
endogenous erythropoietin to maintain hematocrit levels. Figure 2 illustrates how the feedback system 
that regulates Hgb levels is disrupted in ESRD patients. In a patient with a healthy kidney, hypoxia-
inducible transcription factors (HIFs) are activated when the oxygen-carrying capacity of the blood 
decreases below a certain threshold (147-149). Activation of HIFs leads to expression of endogenous 
erythropoietin and subsequent stimulation of erythropoiesis (i.e., the process of RBC production), 
provided that iron is available (150). In ESRD patients, system equilibrium is disturbed when the 
sustained presence of HIFs do not lead to expression of endogenous erythropoietin and subsequent 
stimulation of erythropoiesis. System equilibrium is also disturbed by inflammation, which limits iron 
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 availability for erythropoiesis by down-regulating transferrin (concerned with iron transport) and up-
regulating hepcidin (a hormone that regulates iron availability and absorption) (151, 152).  
 
 
Figure 2. Physiologic model of the feedback system that regulates hemoglobin levels 
 
Adapted from Brookhart et al. (2011) (153).  
 
2. Diagnosis of anemia in ESRD patients   
Routine screening for anemia includes laboratory evaluation of a complete blood count including 
RBC indices, reticulocyte count, serum ferritin concentration, and transferrin saturation (TSAT) or 
reticulate Hgb content. Routine testing for EPO levels in anemic patients is not recommended because 
the test is expensive and patients who respond to exogenous ESAs may have a normal or even elevated 
EPO concentration, which may nevertheless be inappropriately low for the severity of their anemia. 
Recommendations specify that EPO deficiency be a diagnosis of exclusion in the anemic CKD patient. 
The anemia of EPO deficiency is normocytic (normal mean corpuscular volume, or MCV) and 
normochromic (normal mean corpuscular Hgb concentration). A low MCV is suggestive of iron deficiency 
but may be seen in hemoglobinopathies such as thalassemia. A high MCV (macrocytosis) is suggestive 
of vitamin B12 or folate deficiency. Elevated MCV suggest assessment of B12 and folate levels. The serum 
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 ferritin level, which correlates with iron bound to tissue ferritin in the reticuloendothelial system, increases 
in the setting of acute or chronic inflammation independent of tissue iron stores. A TSAT of <16% in an 
anemic patient with CKD is consistent with absolute or functional iron deficiency, both of which are 
characterized by decreased delivery of iron to the eyrthroid marrow. An elevated reticulocyte count is 
inconsistent with EPO deficiency (154). 
 
3. Overview of ESA therapy  
ESA therapy has revolutionized the management of patients with anemia, including ESRD 
patients receiving dialysis. Prior to the approval of ESAs, anemia management was based on RBC 
transfusions. However, RBC transfusions have a number of limitations such as blood supply limitations, 
risk of infection, risk of RBC transfusion reaction, and immune sensitization. Appropriate use of ESA 
therapy and intravenous iron supplementation can effectively manage anemia by raising Hgb levels, 
reducing the need for RBC transfusions, and ultimately improving clinical outcomes (155, 156). Drugs in 
the ESA class are structurally and biologically similar to the naturally occurring protein erythropoietin. 
ESAs stimulate erythropoiesis via the same mechanism as the endogenous glycoprotein hormone 
erythropoietin, through binding of the erythropoietin receptor leading to antiapoptosis of RBC progenitor 
cells and the subsequent production and maturation of RBCs (157, 158). Below, a summary is provided 
for ESAs regarding timeframe for introduction to the U.S. market, indications, contraindications, and 
administration. Since the third-generation ESA methoxy polyethylene glycol-epoetin beta (Mircera) is not 
yet available in the United States, nor is it approved for cancer patients, the discussion focuses on 
epoetin alfa and darbepoetin alfa. 
 
Introduction to the U.S. market. In 1989, the FDA approved epoetin alfa (Epogen/Procrit) (159), the first 
member of the family of ESAs. In 2001, the FDA approved the second-generation ESA darbepoetin alfa 
(Aranesp) (160). These drugs were initially indicated for treatment of anemia, including ESRD patients. 
The FDA approved epoetin alfa and darbepoetin alfa for use in cancer patients in 1993 and 2003, 
respectively. 
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 Indications and contraindications. ESA therapy is indicated for the: a) treatment of anemia due to CKD, 
including patients on dialysis and not on dialysis to decrease the need for RBC transfusion; b) treatment 
of anemia due to zidovudine administered at ≤ 4200 mg/week in HIV-infected patients with endogenous 
serum erythropoietin levels of ≤ 500 mUnits/mL; c) treatment of anemia in patients with non-myeloid 
malignancies where anemia is due to the effect of concomitant myelosuppressive chemotherapy; and d) 
reduction of allogeneic RBC transfusions among patients with perioperative Hgb > 10 to ≤ 13 g/dL who 
are at high risk for perioperative blood loss from elective, noncardiac, nonvascular surgery. ESA therapy 
is not indicated for use: a) in patients with cancer receiving hormonal agents, biologic products, or 
radiotherapy, unless also receiving concomitant myelosuppressive chemotherapy; b) in patients with 
cancer receiving myelosuppressive chemotherapy when the anticipated outcome is cure; c) in patients 
scheduled for surgery who are willing to donate autologous blood; d) in patients undergoing cardiac or 
vascular surgery; or e) as a substitute for RBC transfusions in patients who require immediate correction 
of anemia. ESA therapy is contraindicated in patients with: a) uncontrolled hypertension; b) pure red cell 
aplasia that begins after treatment with ESA therapy; and c) serious allergic reactions to ESA therapy 
(159, 160).  
 
ESA administration. Among U.S. hemodialysis patients, epoetin alfa is the most commonly used ESA 
while darbepoetin alfa is administered infrequently (155). Administration frequency is more burdensome 
for epoetin alfa compared to longer acting darbepoetin alfa. The elimination half-life in humans after a 
single intravenous injection of darbepoetin alfa is three-fold that of epoetin alfa (i.e., 25.3 vs. 8.5 hours). 
Epoetin alfa requires two or three injections per week due to the fairly short circulating half-life of plasma 
EPO (161), whereas darbepoetin alfa requires injections once weekly or once every other week (162). 
Route of administration for ESA therapy is available both intravenously and subcutaneously. In the United 
States, ESA therapy is most commonly administered intravenously for hemodialysis patients per FDA 
recommendations because of the risk of pure red cell aplasia that is associated with the subcutaneous 
route. Internationally, ESA therapy is typically administered subcutaneously to hemodialysis patients 
because of a 20% to 30% dose reduction compared with the intravenous route.  
 
31 
 
 Economic impact. During the last two decades, ESA drugs have had the highest sales worldwide of any 
biologic medication (1). Of $2.8 billion spent in 2010 on injectables for U.S. dialysis patients, ESAs 
accounted for 67%, or $1.87 billion (2). 
 
4. ESA therapy and cancer outcomes 
Beginning in 2003, several reports from randomized clinical trials raised questions regarding the 
safety of ESA therapy in patients with cancer. Of 60 randomized controlled trials in patients with cancer at 
various sites, the majority reported no difference in tumor progression or survival between ESA-treated 
and placebo groups (1). However, eight trials report increased risk of tumor progression and/or death in 
cancer patients treated with ESAs (3-11). Details on these eight trials are presented in Table 5.  
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Table 5. Eight randomized, controlled trials reporting decreased survival and/or decreased locoregional control in ESA-treated patients 
Trial Cancer type 
(n) 
Target Hgb 
(g/dL) 
Actual Hgb 
(g/dL)  
ESA Primary efficacy 
outcome 
Adverse outcome for ESA-
containing arm 
Chemotherapy alone 
BEST (3, 4) Metastatic 
breast  
(n = 939)  
12-14 Md=12.9  
Q1=12.2  
Q3=13.3  
EPO-α 12-month overall 
survival  
Decreased 12-month survival (OS 
at 1 year: 70% (E) vs. 76% (NE), 
HR 1.37, p = 0.01) 
AMG 2000-0161 (6) Lymphoid 
malignancy 
(n = 344)  
13-15 (M)  
13-14 (F)  
Md=11.0 
Q1=9.8  
Q3=12.1 
DPO-α Proportion of 
patients 
achieving a Hgb 
response  
Decreased overall survival (30-day 
survival: 94% (E) vs. 98% (NE) 
11-month survival: 47% (E) vs. 
45% (NE)) 
PREPARE (9) Early breast 
cancer  
(n = 733)  
12.5-13  Md=13.1 
Q1=12.5  
Q3=13.7 
DPO-α Relapse-free and 
overall survival  
Decreased 3-year relapse-free and 
overall survival (DFS at 3 years: 
74.3% (E) vs. 80.0% (NE) HR 
1.31, p = 0.061 
OS: 88% (E) vs. 91.8% (NE), HR 
1.33, p = 0.139) 
GOG-0191 (10) Cervical  
(n = 109)  
12-14  Md=12.7  
Q1=12.1  
Q3=13.3 
EPO-α Progression-free 
and overall 
survival and 
locoregional 
control  
Decreased 3-year progression-free 
and overall survival and 
locoregional control (PFS at 3 
years: 58% (E) vs. 66% (NE) 
OS: 60% (E) vs. 74% (NE)) 
Radiotherapy alone 
ENHANCE (5) Head and 
neck  
(n = 351)  
≥ 15 (M)  
≥ 14 (F)  
Not 
available  
EPO-β Locoregional 
progression-free 
survival  
Decreased 5-year locoregional 
progression-free and overall 
survival (LR-PFS: RR 1.62, p = 
0.0008. 
OS: RR 1.39, p = 0.02) 
DAHANCA-10 (11) Head and 
neck 
(n = 522)  
14-15.5  Not 
available  
DPO-α Locoregional 
disease control  
Decreased locoregional disease 
control (LR control: 56% (E) vs. 
69% (NE), RR 1.44, p = 0.02 
DFS: 48% (E) vs. 63% (NE), RR 
1.49, p = 0.004 
OS: 38% (E) vs. 51% (NE), RR 
1.28, p = 0.08) 
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Chemotherapy and radiotherapy 
EPO-CAN-20 (7) Non-small 
cell lung  
(n = 70)  
12-14 Not available  EPO-α Quality of life  Decreased overall survival (MS: 63 
(E) vs. 129 (NE) days, HR 1.84, p 
= 0.04) 
AMG-2001-103 (8) Non-myeloid 
malignancy 
(n = 989)  
12-13 Md=10.6  
Q1=9.4 
Q3=11.8 
DPO-α RBC transfusions  Decreased overall survival (OS: 
45.7% (E) vs. 48.8% (NE), HR 
1.22, p = 0.022 
Adjusted: HR 1.15, p = 0.121) 
DFS, disease-free survival; DPO-α, darbepoietin alfa; E, ESA treatment arm; EPO-α, erythropoietin alfa; EPO-β, erythropoietin beta; F, female; 
Hemoglobin, Hgb; M, male; Md, median; MS, median survival; HR, hazard ratio; LR, loco-regional; NE, no ESA treatment arm; OS, overall 
survival; PFS, progression-free survival; Q1=25th percentile, Q3=75th percentile. 
 
 The majority of meta-analyses performed report no significant difference between cancer patients 
treated with ESAs compared to placebo (12, 163-165). A 2005 meta-analysis by the Cochrane group 
reported a survival benefit for the ESA group (HR = 0.81; 95% CI, 0.67-0.99). A 2009 meta-analysis by 
the Cochrane group reported higher rates of mortality in the ESA group (HR = 1.06; 95% CI, 1.00-1.12). 
The most recent meta-analysis of 60 experimental studies of more than 15,000 cancer patients failed to 
demonstrate any significant effect of ESAs on survival or disease progression (OR = 1.06; 95% CI, 0.97-
1.15) (12). Contradictory results from these eight trials compared to the majority of trials and the most 
recent meta-analysis may be attributable to a number of study design issues, including: discrepancies 
between the comparison groups, lack of longitudinal tumor assessments, excessively elevated Hgb 
levels, differences in ESA administration, and/or early termination of the trials (1).  
 
5. Timeline of events related to anemia management with ESAs, 2003-2009 
Between 2003 and 2009, a series of events occurred relating to anemia management with ESA 
therapy.  These events included safety reports, FDA black-box warnings, reimbursement changes, and 
revised anemia management guidelines.  
The following is a chronological summary of the relevant studies that preceded and followed the 
March 2007 U.S. FDA advisory on ESAs. August 2003: BEST breast cancer study stopped early due to 
observed higher mortality in ESA group (3); October 2003: ENHANCE head and neck cancer study 
reported poorer locoregional progression-free survival (5); (May 2004): FDA mandates change in ESA 
product labeling to include results of BEST and ENHANCE studies; (April 2005): Meta-analysis among 
cancer patients using ESAs is published and reported 58% increased risk of thromboembolic events 
(non-significant), and suggestive but inconclusive evidence for improved overall survival (166); (May 
2006): Updated meta-analysis among cancer patients using ESAs is published and reported significant 
increase in thromboembolic events, and no association between ESA use and survival and possibly even 
decreased survival for ESA users (165); (November 2006): Publication of results from randomized clinical 
trials in CKD patients (167, 168) that identified risks when targeting patients to Hgb levels above the 
labeled target range of 10–12 g/dL; (February 2007): Publication of two meta-analyses examining the 
effects of treatment with ESAs to higher versus lower Hgb targets in CKD patients (169, 170); (March 
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 2007): FDA black box warning (171) and publication of results from clinical trial in cancer patients 
identifying thromboembolic and mortality risks when treating with ESAs (7); (January 2008): Publication of 
results from clinical trial in cancer patients identifying thromboembolic and mortality risks when treating 
with ESAs (8); (February 2008): Publication of meta-analysis showing elevated risks for thromboembolic 
events and mortality when comparing treatment with ESAs to placebo in patients with cancer (172); (May 
2009): Publication of meta-analysis showing elevated risks for mortality when comparing treatment with 
ESAs to placebo in patients with cancer (173). 
Figure 3 presents a timeline of the major regulatory actions, reimbursement changes, peer-
reviewed publications and revisions to clinical practice guideline recommendations that occurred between 
2005 and 2009. Regidor et al (44) summarized these events as follows: (1) Convening of separate FDA 
drug advisory committee meetings (Oncology Drug Advisory Committee and Cardio-renal Drug Advisory 
Committee and Drug Safety and Risk Management) to evaluate the risk: benefit profile of anemia 
management with ESAs in cancer and kidney disease patients, respectively; (2) Revisions to the ESA 
labels that first removed the target range of 10–12 g/dL: replacement with ‘use the lowest dose to avoid 
the need for RBC transfusions’; addition of a black-box warning highlighting the risks identified when 
targeting Hgb levels of 13.5 and 14 g/dL; subsequently, the Hgb range of 10–12 g/dL was reinstated; 
however, many of the quality of life (QoL) claims were identified as not being adequately supported given 
current standards and were removed, and in the cancer setting, a ‘not indicated’ statement was added for 
patients receiving chemotherapy when the anticipated outcome is cure; (3) FDA and ESA manufacturer 
communications to healthcare professionals regarding changes to the ESA label and the insertion of a 
black-box warning; (4) Revisions to the anemia management guidelines issued by the KDOQI (170), the 
American Society for Clinical Oncology/American Society for Hematology (ASCO/ASH) (174) and the 
National Comprehensive Cancer Network (NCCN) (175); (5) Implementation of a national coverage 
determination in the cancer setting by the Centers for Medicare and Medicaid Services (CMS) restricting 
reimbursement for ESA treatment to an Hgb level <10 g/dL; and (6) Revisions to the erythropoietin 
monitoring policy in dialysis patients reducing payment by 50% if Hgb levels remained >13 g/dL for three 
consecutive months. 
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 Figure 3. A timeline of the major regulatory actions, reimbursement changes, peer-reviewed publications 
and revisions to clinical practice guideline recommendations that occurred between 2005 and 2009 
 
Adapted from Regidor et al. 2011 (44). Regulatory events are presented above the line and all other 
events are described below the line. 
 
 
6. Clinical guidelines & recommendations for ESA therapy 
Over the last decade, the Hgb target range has changed repeatedly as new studies were 
published. Figure 4 lists the recommended Hgb target levels for adult hemodialysis patients on an ESA by 
year and by international group (176). 
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 Figure 4. Hemoglobin target range for adult hemodialysis patients receiving ESA therapy, by year and 
international guideline group 
 
Adapted from McFarlane et al. 2010 (176). Hemoglobin range in g/dL. 
 
 
Management of anemia in dialysis patients with cancer has been challenging due to the absence 
of formal guidelines for providers regarding appropriate usage of ESA therapy in this population. The U.S. 
recommendation for CKD patients on dialysis receiving ESAs is to initiate treatment when the Hgb level is 
less than 10 g/dL and to individualize dosing and use the lowest dose of ESA sufficient to reduce the 
need for RBC transfusions (13), whereas the ESA indication for cancer patients is for treatment of anemia 
due to concomitant myelosuppressive chemotherapy (14). In 2012, KDIGO published clinical practice 
guidelines for anemia in CKD that recommends “using ESA therapy with great caution, if at all, in CKD 
patients with active malignancy—in particular when cure is the anticipated outcome—(1B), a history of 
stroke (1B), or a history of malignancy (2C).” The strength and quality of the KDIGO recommendations 
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 are 1B (i.e., level 1 recommendations with moderate quality of evidence) and 2C (i.e., level 2 suggestions 
with low quality of evidence). As of February 2010, the FDA requires prescribers and hospitals to enroll in 
and comply with the ESA APPRISE Oncology Program requirements in order to prescribe and/or 
dispense ESA therapy to patients with cancer and anemia due to myelosuppressive chemotherapy. Prior 
to each new course of ESA therapy in patients with cancer, prescribers and patients must provide written 
acknowledgment of a discussion of the risks of ESA therapy (159, 160).  
 
7. Anemia management in the ESRD population and the cancer population 
Anemia management, including % ESA use, ESA dosage, % RBC transfusions, and Hgb levels, 
has not been described in ESRD patients with cancer. However, a dramatic shift in anemia management 
has been documented over the last decade in both ESRD patients and cancer patients (Table 6).  
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Table 6. Published studies of ESRD populations or cancer populations that report patterns of ESA utilization and dose in the time period before 
and/or after the March 1, 2007 FDA black-box warning 
Study 
author 
Study 
period 
Study population 
(data source) 
Sample size 
(N) 
% ESA use 
ESRD 
population 
    
Freburger 
(123) 
2002-
2008 
ESRD patients receiving 
hemodialysis therapy (USRDS) 
233,547-
280,400 
The percentage of patients receiving EPO decreased 
from 95% in 2002 to 90% in 2008 
Cancer 
population 
    
Stroupe 
(46) 
2002-
2009 
Adults diagnosed with cancer 
between 2002-2009 (VA) 
257,498 The percentage of patients prescribed an ESA within 12 
months after diagnosis was 8.5%* 
Tarlov 
(45) 
2002-
2008 
Lung and colon cancer patients 
receiving chemotherapy (VA)  
21,239 Any ESA use decreased after the March 2007 FDA 
black-box warning from 36% to 21% for lung cancer 
patients and from 20% to 12% for colon cancer patients 
Wright 
(177) 
1995-
2005 
Breast, lung, or colon cancer patients 
(excluding ESRD patients) diagnosed 
between 1995-2005 and receiving 
chemotherapy (SEER-Medicare) 
24,112 The percentage of patients receiving ESAs increased 
from 71% in 1995 to 86% in 2005 
SEER, Surveillance, Epidemiology, and End Results; VA, United States Department of Veterans Affairs Healthcare System 
*23% of patients received chemotherapy after the FDA black-box warning. 
 
 % ESA use. ESA utilization is very high in the ESRD population on hemodialysis, according to a recent 
study by Freburger et al. Between 2002 and 2008, the percentage of hemodialysis patients receiving ESA 
therapy decreased from 95% to 90% (123). ESA utilization in the cancer population is more variable, with 
reports of between 9% (46) and 86% (177) of cancer patients receiving ESA therapy. In a SEER-
Medicare study of 24,112 breast, lung, and colon cancer patients receiving chemotherapy, the 
percentage of patients receiving ESAs increased from 71% in 1995 to 86% in 2005 (177). In contrast, two 
studies in the VA population reported much lower ESA utilization. Among cancer patients receiving 
chemotherapy, any ESA use decreased after the March 2007 FDA black-box warning from 36% to 21% 
for lung cancer patients and from 20% to 12% for colon cancer patients (45). In a more heterogeneous 
population of cancer patients diagnosed between 2002 and 2009, only 8.5% of cancer patients were 
prescribed an ESA within 12 months after diagnosis (46).  
 
ESA dose. In a study of ESRD patients on hemodialysis, mean monthly EPO dose increased from 
~65,000 units/month in quarter 1 of 2002, to a high of 77,000 units/month by the end of 2006, and then 
decreased to 71,000 units/month by the end of 2008 (123). The mean EPO dose among ESRD patients 
in September 2010 was 72,139 units/month (2). 
 
% RBC transfusions. In the dialysis population, the RBC transfusion rate declined with the introduction 
and routine use of ESA therapy. In prevalent dialysis patients with Medicare parts A and B, RBC 
transfusion rates decreased in both outpatient and inpatient settings from 535 per 1,000 patient-years in 
1992 to 264 per 1,000 patient-years in 2005 (178). 
 
Hgb levels. In a study of ESRD patients between 2002 and 2008, the mean Hgb level was 11.7 g/dL in 
2002 and increased to its peak of 12.1 g/dL in the first quarter of 2007 and then began to decline, and 
reached 11.6 g/dL by the end of 2008 (123). According to the 2012 USRDS Annual Data Report, 69% 
had a Hgb between 10-12 g/dl by the end of 2010, the highest proportion since 1998. The percentage of 
patients with a Hgb >12 g/dl decreased from a peak of 51% to 21% between February 2007 and 
December 2010. The percentage of patients with a Hgb <10 g/dl increased from 6% in the middle of the 
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 decade to 10% by the end of 2010 (2). Among cancer patients diagnosed at the VA between 2002 and 
2009, the average Hgb level that prompted first use of ESA therapy in a patient was lower after the black-
box warning (10.2 vs. 9.6 g/dl) (46). 
 
E. Public health relevance 
This dissertation will contribute to the existing ESRD literature by characterizing the overall and 
site-specific cancer incidence in U.S. hemodialysis patients. The innovative application of competing risks 
methodology to account for the high annual mortality characteristic of the dialysis population will provide 
real-world estimates of cancer incidence, rather than hypothetical estimates that assume no competing 
risks. The results can be used to inform health policy decisions. In addition, this will be the first study to 
document temporal trends in ESA utilization among ESRD patients with cancer. Given the unclear 
association between ESA use and tumor progression and/or decreased survival, the impact of negative 
safety reports in cancer trials, black box advisories, revised anemia management guidelines, and 
reimbursement changes related to ESA therapy is of particular interest. The large and representative 
USRDS dataset will allow identification of important differences by various patient and facility-level 
characteristics in cancer incidence among ESRD patients and ESA utilization in ESRD patients with 
cancer. 
 
CHAPTER III.  METHODS 
A. Study design and population 
Data was utilized from the USRDS, which is a national registry that includes all patients in the 
Medicare ESRD program. For this dissertation work, the study population was restricted to ESRD patients 
≥ 18 years of age who received in-center hemodialysis between April 1, 1995 and December 31, 2010 
and had Medicare as their primary payer with both part A and B coverage in order to insure collection of 
complete claims data on patients. Patients with a history of kidney transplantation or HIV/AIDS were 
excluded to insure that cancer was not due to another cause of immunosuppression. The study 
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 population was limited to patients who remained alive without a cancer diagnosis for at least 9 months 
after dialysis initiation. Three months after the first service date is the amount of time required to process 
Medicare eligibility/enrollment forms and to insure stability in dialysis treatment modality. A subsequent 
six month period (i.e., the baseline period) was required for assessment of comorbidities and functional 
status. The proposed study aims incorporated a retrospective cohort study design with three distinct study 
populations: 
 
1. Study design and population for aims 1a and 1b 
The analyses for aims 1a and 1b utilized a retrospective cohort of all ESRD patients who initiated 
in-center hemodialysis between April 1, 1995 and April 5, 2010 (Figure 5). Patients were observed from 9 
months post-dialysis initiation to the first of the following: the event of interest (i.e., cancer diagnosis); or 
censoring event (i.e., renal replacement therapy modality change to peritoneal dialysis or kidney 
transplantation; end of Medicare as primary payer status; lost-to-follow-up; 5 years since dialysis initiation; 
end of study on December 31, 2010; or death, as appropriate). For aim 1b, death was treated as a 
competing event. 
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Figure 5. Study design for aims 1a and 1b 
 
Study participants are depicted with A) the earliest possible date of dialysis initiation (i.e., April 1, 1995); 
and B) the latest possible date of dialysis initiation (i.e., April 5, 2010). The solid circle denotes dialysis 
initiation. 
 
 
2. Study design and population for Aim 1c 
The analysis for aim 1c utilized 14 annual cohorts (i.e., 1996-2009) of incident and prevalent 
hemodialysis patients that met eligibility criteria by January 1. All ESRD patients who initiated in-center 
hemodialysis on or before April 1 of the previous year and remained alive until January 1 of the current 
year were eligible for that yearly cohort. Patients with cancer during the 6 month baseline period (i.e., July 
4 to December 31 of prior year) were excluded from that yearly cohort. Patients were observed from 9 
months post-dialysis initiation to the first cancer diagnosis. Patients were censored due to the loss of 
Medicare as primary payer status, change of modality, lost-to-follow-up, kidney transplantation, death or 
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 end of study (December 31). As an example, Figure 6 depicts the time periods used to construct the 1996 
annual cohort.  
 
 
Figure 6. Study design for aim 1c, 1996 annual cohort 
 
Study participants consist of prevalent ESRD patients on hemodialysis where April 1, 1995 was the latest 
possible date of dialysis initiation. The solid circle denotes dialysis initiation. 
 
 
3. Study design and population for Aim 2 
The analyses for aim 2 utilized the same retrospective cohort as aim1a, further restricted to 
patients who received their first cancer diagnosis at least 9 months after dialysis initiation, and with post-
cancer diagnosis follow-up time between 2000 and 2010 to ensure a similar distribution of incident and 
prevalent hemodialysis patients over time.  
 
 
B. Data source 
The USRDS is uniquely situated for this research because it is a large, longitudinal population-
based registry with detailed patient-level data capture on all patients in the Medicare ESRD program. The 
USRDS has also helped to inform other cancer studies in ESRD patients (15, 18, 29). All ESRD patients 
in the United States are eligible for Medicare coverage regardless of age, however, some patients remain 
on private or HMO insurance, or have a combination of insurance coverage. All patients diagnosed with 
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 ESRD and initiated on dialysis therapy are entered into the USRDS via the ESRD Medical Evidence 
Report (form CMS-2728) which establishes eligibility for individuals previously not Medicare beneficiaries 
and reclassifies previously eligible beneficiaries as ESRD patients. The dialysis provider is required to 
complete the Medical Evidence Report within 45 days of initiation (2).  
The major source of data for the USRDS is the Renal Beneficiary and Utilization System 
(REBUS), which receives regular updates from the Centers for Medicare and Medicaid Services (CMS) 
based on the Medicare Enrollment Database (EDB), Medicare inpatient and outpatient claims, the Organ 
Procurement and Transplantation Network (OPTN) transplant database, ESRD Medical Evidence Report 
forms (2728) provided by the ESRD networks, ESRD Death Notification forms (2746) obtained from renal 
providers, and the Standard Information Management System (SIMS) database of the ESRD networks. A 
unique patient identifier is common to both the SIMS and CMS databases (2).  
The USRDS comprises data from the patient file, the Medical Evidence Report and Medicare 
Parts A and B claims. The patient file includes information on demographics. The Medical Evidence 
Report collects information on demographics, primary cause of renal failure, and clinical conditions at 
dialysis therapy initiation. Medicare Parts A and B claims include information on diagnoses and 
procedures recorded for all hospitalizations and outpatient visits since dialysis therapy initiation. Medicare 
Part A claims include all hospital inpatient, hospital-based outpatient, skilled nursing facility, home health 
agency, and hospice claims. Medicare Part B physician/supplier claims include durable medical 
equipment charges, physician and other outpatient healthcare provider services (e.g., office-based 
outpatient visits). Medicare Part B institutional claims include monthly data on dialysis care such as total 
EPO dose, number of EPO administrations, and hematocrit values. Medicare requires that the final 
hematocrit value of the month must be submitted with each claim for ESA reimbursement. The facility file, 
which has data from the CMS ESRD Annual Facility Survey and can be linked to dialysis claims by the 
provider ID, contains information on facility characteristics (2). 
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 C. Dependent variable definitions 
1. Cancer outcomes (aim 1) 
Overall and site-specific cancers were ascertained from inpatient and outpatient Medicare claims 
using International Classification of Diseases, 9th revision, Clinical Modification (ICD-9-CM) diagnosis 
codes. Cancer cases were identified using three claims-based algorithms (Table 7), adapted from 
algorithms defined by Setoguchi et al. (179). Definitions 2 and 3 have been reported to have high 
specificity (>98.5%) and relatively high sensitivity (range, 76% to 89%) for identification of incident 
cancers including lung, colorectal, stomach, breast and lymphoma in Medicare data (179). The sensitivity 
for identification of leukemia (definition 2, 52%; definition 3, 74%) is substantially lower than for other sites 
(179). Definition 1 was used for primary analyses because the extended time period of 6 months between 
cancer diagnosis codes allows for delays in health care encounters that may occur due to the high 
severity of illness characteristic of the ESRD population. Definitions 2 and 3 were used in sensitivity 
analyses to assess the impact of different cancer definitions. Dissertation work expanded on these 
definitions to create several more site-specific cancer definitions including lip, tongue, mouth, salivary 
gland, esophagus, stomach, small intestine, anus, liver, gallbladder, pancreas, nasopharynx, larynx, 
trachea, bronchus, mesothelioma, melanoma, connective and other soft tissue, Kaposi sarcoma, ovary, 
testis, vulva, cervix uteri, corpus uteri, penis, kidney, renal pelvis, ureter, bladder, eye, brain, thyroid, 
Hodgkin disease, Non-Hodgkin lymphoma and multiple myeloma. 
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 Table 7. Sensitivity and specificity of claims-based definitions for incident cancers 
 Sensitivity 
(%) 
Specificity (%) 
Definition 1 
≥ 2 cancer diagnoses of cancer within 6 months 
      Lung N/A N/A 
      Colorectal N/A N/A 
      Stomach N/A N/A 
      Breast N/A N/A 
      Lymphoma N/A N/A 
      Leukemia N/A N/A 
Definition 2 
≥ 2 cancer diagnoses of cancer within 2 months 
      Lung 76.19 99.54 
      Colorectal 80.36 99.51 
      Stomach 81.36 99.90 
      Breast 78.89 99.62 
      Lymphoma 79.81 99.81 
      Leukemia 52.20 99.92 
Definition 3 
≥ 1 cancer diagnosis 
      Lung 86.69 98.78 
      Colorectal 88.02 98.51 
      Stomach 89.41 99.75 
      Breast 87.23 98.65 
      Lymphoma 88.71 99.33 
      Leukemia 73.63 99.63 
*Adapted from Setoguchi et al. (2007) (179) 
 
 
A 6-month cancer-free period after dialysis initiation (i.e., the baseline period) was required to 
prevent misclassification of prevalent cases as incident cases (179). Patients with a malignancy-related 
primary cause of ESRD were identified as a prevalent cancer case. Date of cancer onset was defined as 
the first date of a cancer-related diagnosis code in the claims data. In situ carcinomas were included for 
two sites (i.e., breast and bladder) (180). Secondary tumors, benign tumors, and non-melanoma skin 
cancers were excluded. Only the first cancer diagnosis after dialysis initiation was included as an event.  
 
 
2. Anemia management outcomes (aim 2) 
Information on ESAs and hematocrit was identified from dialysis claims from the Medicare Part A 
institutional claims files and Medicare Part A and B claims. Information on transfusions was identified from 
Medicare Part A and B claims. The codes used to identify ESAs and transfusions are presented in 
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 Appendix A (Supplemental Table 19). Monthly outlier values were set to missing if outside the specified 
ranges (EPO dose, 500-700,000 units; hematocrit, 20-60 g/dL) (123). Data were summarized by calendar 
quarter. We calculated the quarterly proportion of the study population treated with ESAs (epoetin alfa 
(EPO), darbepoetin alfa). Mean EPO dose (units/month) was calculated as the quarterly sum of EPO 
doses divided by 3. Darbepoetin alfa dose was excluded from the analysis due to extreme missingness. 
Mean quarterly hemoglobin levels were calculated by dividing hematocrit levels by 3. We calculated the 
quarterly proportion of the study population that received transfusions, as well as the mean number of 
days per year that each patient received a transfusion. 
 
D. Independent variable definitions 
The analyses utilized several covariates from the USRDS and Medicare claims data (Table 8). 
The following information was obtained from the USRDS patient file: first service date, sex, race, primary 
cause of ESRD. Information on ethnicity was obtained from the Medical Evidence file. The earliest date 
for each of the following competing risks and censoring events were identified from the USRDS: change 
in Medicare payer status, change in modality, kidney transplantation, and death. Age at dialysis initiation 
and dialysis vintage (i.e., number of years on dialysis) were calculated by subtracting the first service 
date. History of kidney transplant evaluation was defined as a claim assigned a V-code of V72.83 (other 
specified preoperative examination) during the 6-month baseline period. The sensitivity and specificity of 
code V72.83 has not been reported. Chemotherapy administration was identified using ICD-9-CM 
diagnosis and procedure codes, Healthcare Common Procedure Coding System (HCPCS) codes, and 
revenue codes (Appendix B, Supplemental Table 20) (181, 182). All other variables were used as given in 
the data source.  
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 Table 8. Covariates necessary for statistical analyses of specific aims 
Variable Coding 
Demographics  
    Age at ESRD onset Continuous, categorical 
    Gender Male, female 
    Race White, African American, Other 
    Ethnicity Hispanic, non-Hispanic 
    Primary cause of ESRD Diabetes, hypertension, glomerulonephritis, 
polycystic kidney disease, other 
Clinical  
    Years on dialysis (dialysis vintage) Continuous, categorical 
    Kidney transplant evaluation Yes, no 
    Chemotherapy use Yes, no 
Dates   
    Date of first service (i.e., dialysis initiation) Month/day/year 
    Date of change in Medicare payer status Month/day/year 
    Date of change in dialysis modality Month/day/year 
    Date of first kidney transplantation Month/day/year 
    Date of death Month/day/year 
 
 
E. Statistical analysis for aim 1 
1. Estimation of the cumulative incidence of cancer (aims 1a and 1b) 
For the study cohort of incident dialysis patients, the number and percentage of patients were 
calculated by patient characteristics. Total and average person-years were calculated by patient 
characteristics. For each cancer site, the total number of observed cases was calculated.  
First, we estimated the cumulative incidence of cancer ignoring the competing risk of death (i.e., 
censoring death). Here, the cumulative incidence of cancer at time t is simply the complement of the 
survival function of time until cancer (183). Next, we estimated the cumulative incidence of cancer 
accounting for the competing risk of death. Here, the cumulative incidence is defined as the probability of 
cancer given that an individual has survived up to time t without cancer or has had a competing event of 
death prior to time t. In contrast to the survival function that eliminates individuals who experience the 
competing event from the risk set, the competing risks model specifies that individuals who experience 
the competing event remain in the risk set for the event of interest. Thus, the risk set includes two distinct 
groups: those who have not failed from any cause and those who have previously failed from a competing 
event (184, 185). The cumulative incidence analysis that ignored competing risks was conducted with 
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 standard software (SAS proc lifetest and phreg functions), whereas the analysis that accounted for 
competing risks required a customized SAS program (186).  
In the analysis accounting for the competing risk of death, crude and standardized cumulative 
incidence estimates were stratified by several patient characteristics. We used inverse probability (IP) of 
exposure weights to standardize each stratum to the total study sample at baseline with respect to age, 
sex, race, Hispanic ethnicity, primary cause of ESRD, and calendar year of dialysis initiation, as 
appropriate. IP exposure weights were calculated as the marginal proportion of patients receiving the 
level of exposure they received (i.e., the stabilizing factor) divided by the predicted probability of receiving 
that exposure from the linear-logistic model. For each patient characteristic, we fit both a null linear-
logistic model to calculate the marginal proportion of exposure and a full linear-logistic model to calculate 
the predicted probability of a particular exposure level for each combination of covariates.(186) Age was 
modeled using restricted quadratic splines with 4 knots placed at the 5th, 35th, 65th, and 95th percentiles 
of the age distribution in the study sample (187). Supplemental Table 17 (Appendix A) presents 
descriptive characteristics of the IP exposure weights. 
We also estimated IP of censoring weights to account for informative censoring. First, we 
partitioned the 5-year follow-up period into quintiles defined by the distribution of when patients became 
lost to follow-up (i.e., 1.12, 1.66, 2.31, 3.30 years from dialysis initiation). Then we fit both a null pooled 
linear-logistic model to calculate the marginal probability of remaining uncensored and a full pooled linear-
logistic model to calculate the adjusted predicted probability of remaining uncensored during the quintile 
of follow-up time. IP censoring weights were constructed as defined above, with adjustment for the same 
covariates (186). We obtained 95% CIs as a measure of uncertainty due to sampling error using a 
nonparametric bootstrap. Specifically, we resampled 482,510 patients at random with replacement with 
equal probability 200 times. The standard deviation of the 200 bootstrap resamples was used as an 
estimate of the standard error. SAS software, version 9.3 (Cary, NC) was used for all analyses. 
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 2. Annual incidence rates of cancer (aim 1c) 
For incident and prevalent dialysis patients at risk for cancer in the 1996, 2000, 2004 and 2009 
cohorts, the number and percentage of patients were calculated by patient characteristics. 
The crude annual incidence rates of overall and site-specific cancer were calculated by dividing the total 
number of observed cancer diagnoses during the year by the total patient time at risk. Rates, expressed 
as cancer diagnoses per 100,000 patients per year, were calculated overall and within strata of patient 
characteristics. To derive cancer rates adjusted for temporal trends, standardized mortality ratio (SMR)-
weighted models were created with a weight of 1 for patients diagnosed with cancer in 2000 (the 
comparator group) and a weight of (p/[1- p]) for patients diagnosed with cancer in all other years (1996-
1999 and 2001-2009).  
A multivariable logistic regression model was fit to estimate the propensity score, p, where p 
represents the probability that the patient was diagnosed with cancer in 2000 given a combination of 
covariates used for adjustment. All incidence rates were adjusted for age at dialysis initiation, sex, race, 
ethnicity, primary cause of ESRD, comorbid conditions, functional status and years on dialysis. The 
Joinpoint Regression Program (version 4.0.4, NCI) was used to model trends of adjusted annual 
incidence rates over the entire study period (1996-2009). The Joinpoint Program uses permutation tests 
to find a best fit of regression model with the smallest number of “joinpoints” which are distinct linear 
segments that differ statistically in their slopes. We calculated annual percentage change (APC) and 95% 
CIs, from a log-linear model in the joinpoint analysis using the logarithm of observed rates (188). 
Age-standardized incidence rates were calculated for the U.S. general population (SEER data) 
using the age distribution of our study population of hemodialysis patients with cancer (USRDS data). 
Rates were adjusted to the 2000 U.S. population. 
 
 
3. Sensitivity analysis (aims 1a-c) 
A sensitivity analysis was conducted to assess the influence of various incident and prevalent 
cancer definitions. Incident and prevalent cancer were redefined using the claims-based cancer 
definitions 2 and 3 (Table 7), as described by Setoguchi et al (179). Information from the Medical 
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 Evidence Form Report will not be used in the analysis because of missing data (~10%) and the inability to 
distinguish benign tumors and non-melanoma skin cancer. 
 
 
F. Statistical analysis for aim 2 
We calculated descriptive statistics on the demographic and clinical characteristics of the 
population by year. We also described the annual distribution of cancer diagnoses by cancer site. To 
describe trends in anemia treatment by calendar quarter, we used generalized linear models to generate 
unadjusted and adjusted estimates. Specifically, we used logistic regression models to calculate quarterly 
estimates of the proportion of patients that used ESAs or transfusion, linear regression models to 
calculate mean quarterly estimates of EPO dose (units/month) and hemoglobin levels, and Poisson 
regression models to calculate estimates of the mean number of transfusion days per year. Since EPO 
dose and hematocrit levels were only reported with the administration of ESAs, these analyses were 
restricted to patients who received ESAs at least once during the quarter. Calendar quarter was treated 
as a categorical variable in the models to relax the assumption of linearity. The results section presents 
plots of the adjusted estimates for ESA use, EPO dose, transfusion use, number of transfusion days per 
year, and hemoglobin levels, which are population marginal means that account for changes over time in 
demographic (age, sex, race, ethnicity) and clinical characteristics (primary cause of ESRD, dialysis 
vintage) (189). We stratified estimates by cancer site and chemotherapy use (primary analysis), as well 
as several additional demographic and clinical characteristics (secondary analysis). We further stratified 
the analyses by using three categories of cancer site: a) all cancer sites; b) the most common solid 
tumors in our study population (i.e., cancers of the prostate, female breast, colon/rectum, lung/bronchus, 
kidney/renal pelvis, bladder, and pancreas); and c) hematologic malignancies (i.e., Hodgkin lymphoma, 
non-Hodgkin lymphoma (NHL), leukemia, and myeloma). We performed complete case analyses since 
covariate missingness was less than 1% (i.e., ethnicity (n=134) and race (n=28)). 
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 CHAPTER IV.  RESULTS 
A. Cancer incidence among U.S. Medicare end-stage renal disease patients on hemodialysis, 
1996-2009. 
1. Introduction 
 Despite reports of increased risk of many cancers in the dialysis population (15-17, 22), the 
contemporary cancer burden has not been adequately characterized among patients with end-stage renal 
disease (ESRD) receiving dialysis. Existing estimates of cancer incidence in the ESRD population are 
outdated, primarily focused on all cancer sites combined or a limited number of cancer sites, determined 
from small, select groups of dialysis patients, and failed to account for competing risks of death (15, 16, 
18-39). Furthermore, information is sparse on cancer incidence in dialysis patients by subgroups such as 
age, sex, race, ethnicity, primary cause of ESRD, and years on dialysis.  
 The objective of this study was to describe the cancer burden among ESRD patients receiving 
hemodialysis, overall and among relevant patient subgroups. Using data from the United States Renal 
Data System (USRDS), a national registry including all patients in Medicare’s ESRD program, we 
described temporal trends in cancer incidence rates (1996-2009). In addition, we estimated the 
cumulative incidence of all cancers combined as well as site-specific cancers since dialysis initiation. We 
used competing risk methods to avoid inflating the estimated risk of cancer by censoring the deaths that 
occurred prior to cancer diagnosis (i.e., the event of interest) (40-43). 
 
 
2. Methods 
Data and population 
 We used data from the USRDS, a national registry that includes all patients in Medicare’s ESRD 
program. The study population included ESRD patients ≥ 18 years of age who received in-center 
hemodialysis between April 1, 1995 and December 31, 2010. The study population was restricted to 
individuals with Medicare as their primary payer and both parts A and B coverage in order to ensure 
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 collection of complete claims data on patients. Patients were excluded for a history of kidney 
transplantation, HIV/AIDS, or a malignancy-related primary cause of ESRD. 
The study population was limited to patients who remained alive without a cancer diagnosis for at 
least 9 months after dialysis initiation. This time period was selected because three months after the first 
service date is the amount of time required to process Medicare eligibility/enrollment forms and to ensure 
stability in dialysis treatment modality (190). A subsequent six month period (i.e., the baseline period) was 
required for assessment of comorbidities and functional status, as done previously (191-193). History of 
kidney transplant evaluation was defined as a claim assigned a V-code of V72.83 (other specified 
preoperative examination) during the 6-month baseline period. The sensitivity and specificity of code 
V72.83 has not been reported.  
 
Assessment of Incident Cancers 
 We identified incident site-specific cancers using International Classification of Diseases, 9th 
revision, Clinical Modification (ICD-9-CM) diagnosis codes from inpatient and outpatient Medicare claims. 
Supplementary Table 16 (Appendix A) presents the ICD-9-CM codes used in the site-specific cancer 
definitions. The claims-based algorithm used to define site-specific cancers required ≥ 2 ICD-9-CM 
diagnosis codes within 6 months (179). Date of cancer onset was defined as the first date of a cancer-
related diagnosis code in the claims data. In situ carcinomas were included for two sites (i.e., breast and 
bladder), in accordance with the Surveillance Epidemiology and End Results (SEER) Program (180). 
Secondary tumors, benign tumors, and non-melanoma skin cancers were excluded from the analysis. 
Only the first cancer diagnosis after dialysis initiation was included as an event. Patients diagnosed with 
multiple cancer sites on the same date were included in each site-specific analysis.  
 
Annual Incidence Rates of Cancer 
 We used 14 annual cohorts (i.e., 1996-2009) of prevalent hemodialysis patients that met eligibility 
criteria by January 1 to calculate incidence rates of cancer. All ESRD patients who initiated in-center 
hemodialysis on or before April 1 of the previous year and remained alive until January 1 of the current 
year were eligible for that yearly cohort. Patients were eligible for multiple cohorts. Patients with cancer 
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 during the 6 month baseline period (i.e., July 4 to December 31 of prior year) were excluded from that 
yearly cohort. Patients were observed from 9 months post-dialysis initiation to the first cancer diagnosis. 
Patients were censored due to the loss of Medicare as primary payer status, change of modality, lost-to-
follow-up, kidney transplantation, death or end of study (December 31). 
 The crude annual incidence rates of overall and site-specific cancer were calculated by dividing 
the total number of observed cancer diagnoses during the year by the total patient time at risk. Rates, 
expressed as cancer diagnoses per 100,000 patients per year, were calculated overall and within strata 
of patient characteristics. To derive cancer rates adjusted for secular trends, standardized mortality ratio 
(SMR)-weighted models were created with a weight of 1 for patients diagnosed with cancer in 2000 (the 
comparator group) and a weight of (p/[1-p]) for patients diagnosed with cancer in all other years (1996-
1999 and 2001-2009).  
A multivariable logistic regression model was fit to estimate the propensity score, p, where p 
represents the probability that the patient was diagnosed with cancer in 2000 given a combination of 
covariates used for adjustment. All incidence rates were adjusted for age at dialysis initiation, sex, race, 
ethnicity, primary cause of ESRD, comorbid conditions, functional status and years on dialysis. The 
Joinpoint Regression Program (version 4.0.4, NCI) was used to model trends of adjusted annual 
incidence rates over the entire study period (1996-2009). The Joinpoint Program uses permutation tests 
to find a best fit of regression model with the smallest number of “joinpoints” which are distinct linear 
segments that differ statistically in their slopes. We calculated annual percentage change (APC) and 95% 
CIs, from a log-linear model in the joinpoint analysis using the logarithm of observed rates (188). 
Age-standardized incidence rates were calculated for the U.S. general population (SEER data) 
using the age distribution of our study population of hemodialysis patients with cancer (USRDS data). 
Rates were adjusted to the 2000 U.S. population. 
 
Cumulative Incidence Estimates of Cancer 
We used a retrospective cohort of incident patients who initiated in-center hemodialysis between 
April 1, 1995 and April 5, 2010 to estimate the cumulative incidence of cancer. The retrospective cohort 
design spanned the 5 years after dialysis initiation, including a 3-month eligibility period (to process 
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 Medicare eligibility/enrollment forms and to ensure stability in dialysis treatment modality), a subsequent 
6-month baseline period (to assess comorbidities and functional status), and a follow up period for up to 5 
years after dialysis initiation. Time at risk was measured from 9 months post-dialysis initiation to the first 
of the following: the event of interest (i.e., cancer diagnosis); or censoring (i.e., cancer diagnosis at 
another site; renal replacement therapy modality change to peritoneal dialysis or kidney transplantation; 
end of Medicare as primary payer status; lost-to-follow-up; 5 years since dialysis initiation; end of study on 
December 31, 2010; or death, as appropriate).  
First, we estimated the cumulative incidence of cancer ignoring the competing risk of death (i.e., 
censoring death). Here, the cumulative incidence of cancer at time t is simply the complement of the 
survival function of time until cancer (183). Next, we estimated the cumulative incidence of cancer 
accounting for the competing risk of death. Here, the cumulative incidence is defined as the probability of 
cancer given that an individual has survived up to time t without cancer or has had a competing event of 
death prior to time t. In contrast to the survival function that eliminates individuals who experience the 
competing event from the risk set, the competing risks model specifies that individuals who experience 
the competing event remain in the risk set for the event of interest. Thus, the risk set includes two distinct 
groups: those who have not failed from any cause and those who have previously failed from a competing 
event (184, 185). The cumulative incidence analysis that ignored competing risks was conducted with 
standard software (SAS proc lifetest and phreg functions), whereas the analysis that accounted for 
competing risks required a customized SAS program (186).  
In the analysis accounting for the competing risk of death, crude and standardized cumulative 
incidence estimates were stratified by several patient characteristics. We used inverse probability (IP) of 
exposure weights to standardize each stratum to the total study sample at baseline with respect to age, 
sex, race, Hispanic ethnicity, primary cause of ESRD, and calendar year of dialysis initiation, as 
appropriate. IP exposure weights were calculated as the marginal proportion of patients receiving the 
level of exposure they received (i.e., the stabilizing factor) divided by the predicted probability of receiving 
that exposure from the linear-logistic model. For each patient characteristic, we fit both a null linear-
logistic model to calculate the marginal proportion of exposure and a full linear-logistic model to calculate 
the predicted probability of a particular exposure level for each combination of covariates (186). Age was 
57 
 
 modeled using restricted quadratic splines with 4 knots placed at the 5th, 35th, 65th, and 95th percentiles of 
the age distribution in the study sample (187). Supplemental Table 17 (Appendix A) presents descriptive 
characteristics of the IP exposure weights. 
We also estimated IP of censoring weights to account for informative censoring. First, we 
partitioned the 5-year follow-up period into quintiles defined by the distribution of when patients became 
lost to follow-up (i.e., 1.12, 1.66, 2.31, 3.30 years from dialysis initiation). Then we fit both a null pooled 
linear-logistic model to calculate the marginal probability of remaining uncensored and a full pooled linear-
logistic model to calculate the adjusted predicted probability of remaining uncensored during the quintile 
of follow-up time. IP censoring weights were constructed as defined above, with adjustment for the same 
covariates (186). We obtained 95% CIs as a measure of uncertainty due to sampling error using a 
nonparametric bootstrap. Specifically, we resampled 482,510 patients at random with replacement with 
equal probability 200 times. The standard deviation of the 200 bootstrap resamples was used as an 
estimate of the standard error. SAS software, version 9.3 (Cary, NC) was used for all analyses. 
 
3. Results 
Annual Incidence Rates of Cancer 
Table 9 describes characteristics of the study population of incident and prevalent dialysis 
patients for selected years of the study period. Over time, the number of patients per cohort increased. 
Patients were more likely to be male, white, or have diabetes as the primary cause of ESRD in recent 
cohorts. In addition, mean age and mean duration of dialysis increased over the study period.  
Adjusted annual incidence rates of cancer are presented in Figure 7. We observed a constant 
rate of incident cancer diagnoses for all sites from 1996-2009, from 3923 to 3860 cases per 100,000 
person years [annual percentage change (APC), 0.1; 95% confidence interval (CI), -0.4, 0.6]. Between 
1996-2009, incidence rates increased for cancers of the kidney/renal pelvis, decreased for cancers of the 
colon/rectum, lung/bronchus, pancreas, and other sites (1996-2003 only), and remained constant for 
cancers of the prostate, female breast, bladder, NHL, and other sites (2003-2009 only). Across all 
calendar years, cancers of the prostate and female breast were the most commonly diagnosed, 
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 representing 1195 and 718 cases per 100,000 person years in 2009, respectively. Crude rates are 
presented in Supplemental Figure 17 (Appendix A).  
Figure 8 presents adjusted incidence rates for the four most frequently diagnosed cancer sites 
stratified by subgroups. Adjusted incidence rates were much higher among older patients, males, or 
whites and less common among patients with diabetes as the primary cause of ESRD. Prostate cancer 
had the highest incidence rate across all but four strata (i.e., <65 years, female, non-white, or diabetes as 
primary cause of ESRD). 
Between 1996-2009, the unadjusted incidence rate estimate for all cancer sites was almost three 
times higher in the dialysis population compared to the age-standardized rate in the U.S. general 
population (3788 vs. 1348 cases/100,000 person-years). Similarly, incidence rate estimates were higher 
in the dialysis population for all eight of the most common incident site-specific cancers diagnosed in the 
study population. Rates were most elevated for cancers of the kidney/renal pelvis (417 vs. 51 
cases/100,000 person-years) and pancreas (168 vs. 43 cases/100,000 person-years) compared to the 
U.S. general population (Appendix A, Supplemental Table 13). 
 
Cumulative Incidence Estimates of Cancer 
Of 482,510 patients who met study eligibility requirements (Appendix A, Supplemental Figure 18), 
48.4% were female, 62.7% were white, 32.0% were African American, and 13.1% were Hispanic. The 
most common reported causes of ESRD were diabetes (50.4%) and hypertension (30.5%). Median age 
at dialysis initiation was 67 years (Appendix A, Supplemental Table 14). Median length of follow-up after 
dialysis initiation was 2.5 years. 
 During 988,395 person-years of follow-up between 9 months and 5 years after dialysis initiation, 
37,128 patients were diagnosed with cancer. A total of 217,773 (45.1%) patients died prior to receipt of a 
cancer diagnosis. Twelve percent (n=57,345) of the 482,510 patients were censored alive and cancer-
free before 5-years of follow-up or December 31, 2010.  
The 5-year crude cumulative incidence of any cancer was substantially lower in the analysis that 
did not censor deaths (9.48%; 95% CI, 9.39% to 9.57%) compared to the analysis that censored deaths 
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 (13.86%; 95% CI, 13.71% to 14.01%) (Table 10). Figure 9 illustrates the divergence of these cumulative 
incidence estimates with increasing time since dialysis initiation.  
Table 11 presents crude and standardized 5-year cumulative incidence estimates of any cancer 
accounting for death as a competing risk, stratified by patient characteristics. Figure 10 and supplemental 
figure 19 (Appendix A) present standardized and crude cumulative incidence estimates accounting for 
death as a competing risk, by time from dialysis initiation, respectively. Results were not meaningfully 
altered when drop-out was not accounted for in the analysis (~1% change) (results not shown). After 
accounting for case-mix characteristics measured at baseline and the competing risk of death, the 5-year 
cumulative incidence of any cancer was higher among the following patient subgroups: ≥ 65 years at 
dialysis initiation (11.28%); males (10.93%); non-whites (9.79%); non-Hispanics (9.65%); primary ESRD 
cause other than diabetes (hypertension, 10.39%; other, 11.54%; glomerulonephritis, 12.01%); dialysis 
initiation between 2003-2010 (9.75%); and history of kidney transplant evaluation (11.67%). 
Supplemental figure 4 presents crude cumulative incidence estimates that censored deaths, stratified by 
patient characteristics. 
Table 10 and Supplemental Table 15 (Appendix A) present results from more and less common 
site-specific cancer analyses (i.e., ≥150 and <150 site-specific cancer cases over the study period). The 
most frequently diagnosed cancer sites were prostate (n=5,396), lung/bronchus (n=4,969), colon/rectum 
(n=4,360), female breast (n=3,688), kidney/renal pelvis (n=2,805), bladder (n=2,216), non-Hodgkin 
lymphoma (n=1,284), leukemia (n=1,077), myeloma (n=1,024), and pancreas (n=928). For all site-specific 
cancers, the 5-year cumulative incidence estimate was lower in the competing risks analysis compared to 
the analysis that censored deaths.  
 
4. Discussion 
We conducted a large national study of ESRD patients undergoing hemodialysis to describe the 
incidence of cancer in this population. After accounting for the substantial competing risk of death in the 
ESRD population undergoing dialysis, we observed a high cumulative incidence of cancer, with over 9% 
of the ESRD population being diagnosed with cancer over a 5-year period after initiating dialysis. 
Between 1996-2009, we observed constant rates of incident cancer diagnoses for all sites combined, but 
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 identified trends of increasing and decreasing incidence rates for some site-specific cancers. There are 
no previous population-based estimates of cumulative incidence or annual incidence rates of cancer in 
the dialysis population, therefore these estimates provide important new information on the cancer burden 
in this unique population. In addition, our results demonstrate varying patterns of cancer incidence in 
subgroups, after accounting for measured patient characteristics.  
Our 5-year cumulative incidence estimate of 9.48% depends on the risk of both cancer and the 
competing event of death that precludes development of cancer. In contrast, the analysis that censored 
deaths yielded a much higher 5-year cumulative incidence estimate of 13.86%, representing the risk of 
cancer in the dialysis population assuming that all deaths could be prevented. This estimate of cancer risk 
was higher than the estimate that accounted for the competing risk of death because standard survival 
analysis techniques implicitly allow for some censored deaths to later become cancer cases after death. 
The competing risk approach provides an estimate of the total amount of cancer diagnoses that will occur 
in the population, which is valuable for health care policy and planning in the dialysis population 
characterized by very high mortality (194).  
We observed higher incidence rates of cancer in the dialysis population compared to the U.S. 
general population, suggesting that ESRD patients are uniquely at risk for developing cancer while 
receiving hemodialysis treatment. Our findings are consistent with previous population-based studies of 
cancer in the dialysis population which have reported increased risk for any cancer (SIR range, 1.2-2.0) 
and several site-specific cancers compared to the general population (15, 16, 22). One exception is a 
recent SEER-Medicare study restricted to patients >65 years that reported no increased overall risk of 
cancer in ESRD patients compared to the general population (23). This discrepancy may be due to 
inadvertent inclusion of non-ESRD patients with less severe kidney disease, with reportedly lower risk of 
cancer than ESRD patients on dialysis (16). 
Several explanations have been proposed for increased cancer incidence in the dialysis population, 
including ESRD-associated immunodeficiency and nutritional abnormalities (130-138).  Excess cancer 
risk may also be due to an interaction of uremic and dialysis-induced immune dysfunction with 
established risk factors such as UV radiation, tobacco, or alcohol (16). Recently, there has been a focus 
on the potential role of erythropoietin stimulating agents (ESAs), commonly used to manage anemia, in 
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 carcinogenesis. ESAs are known to activate erythropoietin receptors on the surface of cancer cells. 
Additionally, erythropoietin-induced angiogenesis may promote tumor growth (1, 139). Yet, we did not 
observe temporal trends in overall cancer incidence that correlate with the documented rise and fall of 
ESA use and dose (123). Instead, we observed constant incidence rates over the study period, which 
suggests that ESA therapy is not related to increased cancer incidence.  
One explanation for subgroup differences in 5-year cumulative incidence estimates of cancer could 
be differences in mortality. In our analysis that censored deaths, we observed that 5-year cumulative 
incidence was similar by era of dialysis initiation. In contrast, the competing risks approach (which allowed 
patients who died to remain in the denominator of patients at risk) yielded a higher 5-year cumulative 
incidence estimate among patients who initiated dialysis in 2003-2010 versus 1995-2002. This suggests 
that higher cancer incidence in the most recent era is due to improved survival in the dialysis population. 
We observed a similar pattern in the comparison between patients with and without kidney transplant 
evaluation, in which patients with evaluation had higher cancer incidence due to longer survival.  
Another explanation for higher 5-year cumulative incidence of cancer among patients who received 
kidney transplant evaluation, despite a healthier profile than patients who did not receive evaluation, are 
unexpected cancer diagnoses yielded by intensive medical workup involving comprehensive cancer 
screening (70). Our finding should be interpreted cautiously due to unknown validity of the code used to 
define kidney transplant evaluation. In addition, the diffusion curve was a monotonic linear increase in 
annual use over the study period (i.e., 0% to 10%), raising concern about reliability of the kidney 
transplant evaluation code over time.   
Our findings are subject to several limitations. First, claims-based cancer definitions have not been 
validated in the ESRD population. Second, the possibility of overestimating cancer incidence due to 
misclassification of prevalent cases as incident cases cannot be excluded. However, identification of 
prevalent cases of cancer during the 6-month baseline period minimized the possibility of 
misclassification. Third, use of claims-based definitions of cancer made it impossible to determine 
whether cancers identified as incident cases were truly new primaries, metastases, or histories of cancer 
miscoded as new primaries. Lastly, information on cancer risk factors was absent from the USRDS data. 
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 Strengths of our study include more than a decade of data on the large and representative population 
of U.S. ESRD patients on hemodialysis. The large sample size allowed characterization of cancer 
incidence within subgroups. Additionally, competing risks methodology is an innovative approach 
appropriate for the inherent competing risks problem in the dialysis population due to high annual 
mortality.  
There are currently no standard recommendations for cancer screening (i.e., KDIGO, KDOQI) in the 
dialysis population. Our study demonstrates that overall risk of cancer among dialysis patients is higher 
than among the general population. Yet, the life-expectancy of individuals receiving dialysis is lower than 
the general population, and previous cost-effectiveness analyses have suggested general cancer 
screening would add minimal days of life saved per person (2, 140, 141). In practice, cancer screening in 
dialysis patients has been provided on an individualized patient-focused manner based on the patient’s 
cancer risk factors, expected survival, and transplant status (141). Our findings highlight the need to 
potentially reevaluate cancer screening practices among certain subgroups. Furthermore, targeted 
screening for certain cancer types should be considered.   
In conclusion, we reported a high and constant overall burden of cancer among ESRD patients 
receiving hemodialysis, with certain subgroups of the population exhibiting a particularly elevated cancer 
risk. 
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Table 9. Demographic and clinical characteristics of annual study cohorts at risk for cancer in 1996, 2000, 
2004, and 2009 
 Yeara 
Characteristics 1996 2000 2004 2009 
Patients (n) 88,676 110,897 142,142 164,214 
Age at dialysis initiation 
(years), mean (sd) 
61.3 (14.8) 62.1 (14.7) 62.7 (14.6) 62.5 (14.5) 
Age at dialysis initiation (years)     
     18-44 15.0 13.7 12.2 11.8 
     45-64 35.8 36.0 37.6 40.4 
     65-74 30.3 28.6 26.7 25.1 
     ≥75 18.9 21.7 23.5 22.7 
Male sex 49.5 50.3 51.5 52.6 
White race 51.4 51.4 52.4 53.0 
Reported cause of ESRD     
     Diabetes 35.4 42.3 46.2 48.4 
     Hypertension 32.3 30.5 30.0 29.6 
     Glomerulonephritis 13.1 13.0 11.6 10.3 
     Other 19.2 14.2 12.3 11.7 
Duration of dialysis (years), 
mean (sd) 
3.5 (3.4) 3.6 (3.3) 3.6 (3.3) 3.9 (3.5) 
Duration of dialysis (years)     
     0-1 30.7 30.2 28.3 25.1 
     2-5 51.3 50.3 51.5 51.3 
     >5 18.0 19.5 20.3 23.6 
History of kidney transplant 
evaluation 
    
     No 100.0 95.7 93.8 90.0 
     Yes 0.0 4.3 6.7 10.0 
aJanuary 1 of respective years. 
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 Table 10. The crude 5-year cumulative incidence of site-specific cancers among U.S. hemodialysis 
patients 
  5-year cumulative incidence % (95% CI) 
Cancer site No. of patients Death treated as  
censoring event 
Death treated as  
competing event 
Lip, oral cavity, and pharynx    
    Tongue 156 0.07 (0.06, 0.08) 0.04 (0.04, 0.05) 
    Mouth 191 0.08 (0.07, 0.09) 0.05 (0.04, 0.06) 
    Pharynx 183 0.08 (0.07, 0.09) 0.05 (0.05, 0.06) 
Digestive system    
    Esophagus 369 0.16 (0.14, 0.17) 0.10 (0.09, 0.11) 
    Stomach 590 0.25 (0.23, 0.27) 0.16 (0.15, 0.18) 
    Colon/rectum 4,360 1.76 (1.70, 1.82) 1.18 (1.15, 1.22) 
    Liver 865 0.36 (0.33, 0.39) 0.24 (0.22, 0.26) 
    Gallbladder 202 0.08 (0.07, 0.10) 0.06 (0.05, 0.06) 
    Pancreas 928 0.39 (0.36, 0.42) 0.26 (0.24, 0.28) 
Respiratory system    
    Larynx 318 0.13 (0.11, 0.14) 0.09 (0.08, 0.10) 
    Lung/bronchus 4,969 2.03 (1.97, 2.09) 1.36 (1.32, 1.39) 
Bone and cartilage 206 0.09 (0.07, 0.10) 0.06 (0.05, 0.07) 
Skin/connective tissuea    
    Melanoma 872 0.36 (0.33, 0.39) 0.24 (0.22, 0.26) 
    Connective & other soft tissue 285 0.12 (0.10, 0.13) 0.08 (0.07, 0.09) 
Reproductive and genitourinary    
    Breast (female) b 3,688 1.48 (1.43, 1.53) 1.00 (0.97, 1.03) 
    Cervix uteri 345 0.14 (0.12, 0.15) 0.09 (0.08, 0.10) 
    Corpus and uterus 551 0.23 (0.21, 0.25) 0.15 (0.14, 0.16) 
    Ovary 341 0.14 (0.12, 0.16) 0.09 (0.08, 0.10) 
    Prostate 5,396 1.98 (1.93, 2.04) 1.41 (1.37, 1.44) 
    Bladder b 2,216 0.84 (0.80, 0.88) 0.59 (0.56, 0.61) 
    Kidney/renal pelvis 2,805 1.14 (1.09, 1.19) 0.76 (0.73, 0.79) 
Neurological    
    Brain and other nervous 
system 
560 0.23 (0.21, 0.25) 0.15 (0.14, 0.17) 
Endocrine    
    Thyroid 337 0.14 (0.12, 0.16) 0.09 (0.08, 0.10) 
Hematological    
    Non-Hodgkin lymphoma 1,284 0.51 (0.48, 0.55) 0.35 (0.33, 0.37) 
    Myeloma 1,024 0.40 (0.37, 0.43) 0.27 (0.26, 0.29) 
    Leukemia 1,077 0.43 (0.40, 0.46) 0.29 (0.27, 0.31) 
Ill-defined and unspecified 1,941 0.81 (0.77, 0.85) 0.53 (0.51, 0.56) 
All sites 37,128c 13.86 (13.71, 14.01) 9.48 (9.39, 9.57) 
Data presented for cancer sites with ≥150 cases over the study period. Supplemental Table 15 (Appendix 
A) presents results for cancer sites with <150 cases. 
aExcludes non-melanoma skin cancer 
bMalignant and carcinoma in situ 
cThe total number of patients with site-specific cancer diagnoses exceeds the total number of patients 
with any cancer because 667 patients were diagnosed with multiple cancer sites on the same date. 
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Table 11. Crude and standardized 5-year cumulative incidence estimates of any cancer, accounting for 
the competing risk of death, by demographic and clinical characteristics  
 5-year cumulative incidence % (95% CI) 
 Crude Standardizeda 
Age at dialysis initiation   
    18-44 years 3.91 (3.70, 4.11) 3.81 (3.55, 4.06) 
    45-64 years 7.83 (7.65, 8.00) 8.07 (7.89, 8.25) 
    ≥ 65 years 11.17 (11.05, 11.29) 11.28 (11.15, 11.42) 
Sex   
    Male 10.59 (10.46, 10.71) 10.85 (10.73, 10.99) 
    Female 8.23 (8.10, 8.36) 8.15 (8.01, 8.28) 
Race   
    White 9.75 (9.62, 9.87) 9.36 (9.23, 9.48) 
    Non-white 9.05 (8.91, 9.19) 9.79 (9.57, 10.00) 
Ethnicity   
    Hispanic 7.17 (6.92, 7.41) 8.57 (7.84, 9.30) 
    Non-Hispanic 9.83 (9.73, 9.93) 9.65 (9.54, 9.75) 
Reported cause of ESRD   
    Diabetes 8.14 (8.02, 8.26) 8.30 (8.18, 8.42) 
    Hypertension 10.78 (10.60, 10.97) 10.39 (10.19, 10.59) 
    Glomerulonephritis 10.52 (10.18, 10.87) 12.01 (11.59, 12.43) 
    Other 11.36 (11.05, 11.67) 11.54 (11.20, 11.89) 
Calendar period of dialysis initiation   
    1995-2002 9.26 (9.15, 9.37) 9.14 (9.02, 9.25) 
    2003-2010 9.65 (9.51, 9.79) 9.75 (9.60, 9.89) 
History of kidney transplant 
evaluation 
  
    No 8.90 (8.79, 9.00) 8.70 (8.59, 8.80) 
    Yes 10.93 (10.74, 11.12) 11.65 (11.44, 11.86) 
aStandardized cumulative incidence estimates account for case-mix characteristics (age at dialysis 
initiation, sex, race, ethnicity, primary cause of ESRD, year of dialysis initiation) measured at baseline 
using inverse-probability weights. 
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 Figure 7. Adjusted annual incidence rates of cancer diagnoses among U.S. hemodialysis patients by 
cancer site, 1996-2009 
 
Adjusted annual incidence rates of cancer diagnoses for all sites remained constant [annual percentage 
change (APC), 0.1; 95% confidence interval (CI), -0.4, 0.6]. Incidence rates increased for cancers of the 
kidney/renal pelvis [APC, 2.0; 95% CI, 0.9, 3.2], decreased for cancers of the colon/rectum [APC, -1.4; 
95% CI, -2.0, -0.8], lung/bronchus [APC, -0.8; 95% CI, -1.5, -0.1], pancreas [APC, -2.5; 95% CI, -3.8, -
1.3], and other sites (1996-2003 only) [APC, -2.8; 95% CI, -4.3, -1.3], and remained constant for cancers 
of the prostate [APC, -0.2; 95% CI, -1.2, 0.8], female breast [APC, -0.3; 95% CI, -1.5, 0.9], bladder [APC, 
-1.1; 95% CI, -2.3, 0.1], NHL [APC, -1.1; 95% CI, -2.4, 0.2], and other sites (2003-2009 only) [APC, 1.7; 
95% CI, -0.5, 3.9]. Rates were adjusted for age, sex, race, cause of ESRD, and years on dialysis. 
Incident cases were defined as the first cancer diagnosis of the year among patients without a history of 
cancer in the last 6 months of the previous calendar year. Other cancers were defined as all other site-
specific cancers (e.g., cancers of the esophagus, stomach, liver, etc.). The sum of the site-specific cancer 
rates exceeds the rate for any cancer, due to patients diagnosed with multiple cancer sites on the same 
date. 
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 Figure 8. Adjusted cancer incidence rates for cancers of the prostate, breast (female), lung/bronchus, and 
colon/rectum among U.S. hemodialysis patients, by demographic and clinical characteristics, 1996-2009 
 
Incident cases were defined as the first cancer diagnosis of the year among patients without a history of 
cancer in the last 6 months of the previous calendar year. Rates were adjusted for age, sex, race, cause 
of ESRD, and years on dialysis. Age adjustment was performed for four strata (18-44, 45-64, 65-74, ≥75 
years), although only two categories are presented due to limited case numbers in the 18-44 age group. 
The subgroup of interest was omitted from the adjustment for each respective subgroup category.  
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 Figure 9. The crude cumulative incidence of any cancer by time since dialysis initiation among U.S. 
hemodialysis patients 
 
 
Cumulative incidence estimates were substantially lower in the analysis that treated death as a competing 
event versus a censoring event.  
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 Figure 10. The standardized cumulative incidence of any cancer by time since dialysis initiation, 
accounting for the competing risk of death, by demographic and clinical characteristics 
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Figures were stratified by patient characteristics including (A) age at dialysis initiation; (B) sex; (C) race; 
(D) ethnicity; (E) primary cause of ESRD; (F) year of dialysis initiation; and (G) history of kidney transplant 
evaluation. Cumulative incidence functions were standardized to the total study population by combining 
the cumulative incidence function with inverse probability of exposure weights that account for case-mix 
characteristics (age at dialysis initiation, sex, race, ethnicity, primary cause of ESRD, year of dialysis 
initiation) measured at baseline. 
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 B. Trends in use of erythropoiesis-stimulating agents and blood transfusions in U.S. hemodialysis 
patients with cancer 
1. Introduction 
Erythropoiesis-stimulating agents (ESAs) have been widely used for anemia management in both 
end-stage renal disease (ESRD) patients undergoing dialysis and cancer patients to increase hemoglobin 
levels, reduce the need for red blood cell transfusions, and alleviate anemia-related symptoms. In May 
2004, the United States Food and Drug Administration (FDA) mandated the first of an increasingly 
restrictive series of product labeling changes for the ESA class of drugs in response to reports of 
increased mortality in patients with cancer (195). In March 2007, the FDA mandated the addition of a 
black-box warning for ESA drugs due to reports of increased risk of death and serious cardiovascular 
events in patients with chronic kidney disease and increased risk of tumor progression and/or death in 
patients with cancer when hemoglobin levels were greater than 12.0 g/dL (196). This advisory was 
quickly followed by revisions of clinical guidelines for ESA use (170, 174, 197). Also in 2007, the Centers 
for Medicare and Medicaid Services published a National Coverage Decision to limit reimbursement for 
ESA administration and tie reimbursement to specific hemoglobin levels and time schedules (198). 
Clinical guidelines have been regularly updated as emerging safety data has become available. 
After several years of escalating ESA use in both the dialysis population and the cancer 
populations, anemia management patterns changed markedly during and after the period of negative 
safety reports, product labeling changes, black box advisories, revised anemia management guidelines, 
and reimbursement changes. Recent declines in ESA use, ESA dose, and hemoglobin levels have been 
reported in several national studies of cancer populations or dialysis populations (45, 123, 199-203). 
However, no information exists regarding trends in anemia treatment among dialysis patients also 
diagnosed with cancer. 
 A cancer diagnosis complicates anemia management in dialysis patients for many reasons. First, 
there are additional safety concerns associated with ESA treatment in the cancer population including 
tumor progression, thromboembolic complications, and mortality (204, 205). Beginning in 2003, eight 
randomized clinical trials in cancer patients reported increased risk of tumor progression and/or death 
among cancer patients treated with ESAs (3-11). The most recent meta-analyses of cancer patients 
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 demonstrated significant effects of ESAs on increased thromboembolic events and mortality but not on 
disease progression (206). Second, there are currently no formal guidelines for providers regarding 
appropriate usage of ESAs in ESRD patients with cancer (205). For patients undergoing dialysis, the 
United States recommendation is to initiate treatment when the hemoglobin level is less than 10 g/dL and 
to individualize dosing and use the lowest dose of ESA sufficient to reduce the need for transfusions (13). 
For cancer patients, the recommendations are similar except the ESA indication for treatment of anemia 
is restricted to patients undergoing myelosuppressive chemotherapy (14). Third, little is known regarding 
patterns of ESA use in dialysis patients with cancer. In this population, it remains unclear how anemia 
treatment has been affected by recent clinical and policy events. 
The objectives of this study were to examine trends in anemia management in the U.S. 
hemodialysis population after the diagnosis of cancer. Using population-based data from the United 
States Renal Data System (USRDS), a national registry including all patients in Medicare’s ESRD 
program, we described patterns of use of ESAs and transfusions as well as resulting hemoglobin levels. 
We also examined anemia management patterns within subgroups, including cancer site and 
chemotherapy use. We report trends from 2000 to 2010, a time period that includes data before and after 
negative safety reports, product labeling changes, black box advisories, revised anemia management 
guidelines, and reimbursement changes. 
 
2. Methods 
Study Population 
Using data from the USRDS, a national registry of patients in Medicare’s ESRD program, we 
identified all ESRD patients ≥ 18 years who received in-center hemodialysis between April 1, 1995 and 
December 31, 2010 with Medicare as their primary payer and both parts A and B coverage. We restricted 
the cohort to patients who received their first cancer diagnosis at least 9 months after dialysis initiation. 
This time period was to ensure stability in dialysis treatment modality (months 0-3 post-dialysis initiation) 
(190), and to exclude prevalent cancer cases identified using Medicare claims (months 3-8 post-dialysis 
initiation), as previously described (191-193). Patients with a malignancy-related primary cause of ESRD 
or a history of kidney transplantation or HIV/AIDS were also excluded. We further restricted the cohort to 
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 patients with post-cancer diagnosis follow-up time between 2000 and 2010, to ensure a similar 
distribution of incident and prevalent hemodialysis patients over time.  
 
Incident Cancer Definitions 
 We identified incident site-specific cancers using International Classification of Diseases, 9th 
revision, Clinical Modification (ICD-9-CM) diagnosis codes from inpatient and outpatient Medicare claims 
(Appendix B, Supplemental Table 18). Site-specific cancers were defined by ≥ 2 ICD-9-CM diagnosis 
codes within 6 months (179). Date of cancer onset was defined as the first date of a cancer-related 
diagnosis code in the claims data. In situ carcinomas were included for two sites (i.e., breast and bladder) 
(180). Secondary tumors, benign tumors, and non-melanoma skin cancers were excluded. Only the first 
cancer diagnosis after dialysis initiation was included as an event.  
 
Anemia Therapy Outcomes 
Information on ESAs and hematocrit was identified from dialysis claims from the Medicare Part A 
institutional claims files and Medicare Part A and B claims. Information on transfusions was identified from 
Medicare Part A and B claims. The codes used to identify ESAs and transfusions are presented in 
Supplemental Table 19 (Appendix B). Monthly outlier values were set to missing if outside the specified 
ranges (EPO dose, 500-700,000 units; hematocrit, 20-60 g/dL) (123). Data were summarized by calendar 
quarter. We calculated the quarterly proportion of the study population treated with ESAs (epoetin alfa 
(EPO), darbepoetin alfa). Mean EPO dose (units/month) was calculated as the quarterly sum of EPO 
doses divided by 3. Darbepoetin alfa dose was excluded from the analysis due to extreme missingness. 
Patients treated at a hospital-based facility were excluded from the EPO dose calculation to remove the 
possibility of simultaneous treatment with EPO and darbepoetin alfa. Mean quarterly hemoglobin levels 
were calculated by dividing hematocrit levels by 3. We calculated the quarterly proportion of the study 
population that received transfusions, as well as the mean number of days per year that each patient 
received a transfusion. 
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 Covariates 
We obtained the following information from the USRDS patient file: first service date, sex, race, 
primary cause of ESRD. Information on ethnicity was obtained from the Medical Evidence file. For each 
calendar quarter, age at dialysis initiation and duration of dialysis (i.e., vintage) were calculated on the 
first date of the quarter by subtracting the first service date. We identified chemotherapy administration 
during each quarter using ICD-9-CM diagnosis and procedure codes, Healthcare Common Procedure 
Coding System (HCPCS) codes, and revenue codes (Appendix B, Supplemental Table 20) (181, 182).  
 
Statistical Analysis 
We calculated descriptive statistics on the demographic and clinical characteristics of the 
population by year. We also described the annual distribution of cancer diagnoses by cancer site. To 
describe trends in anemia treatment by calendar quarter, we used generalized linear models to generate 
unadjusted and adjusted estimates. Specifically, we used logistic regression models to calculate quarterly 
estimates of the proportion of patients that used ESAs or transfusion, linear regression models to 
calculate mean quarterly estimates of EPO dose (units/month) and hemoglobin levels, and Poisson 
regression models to calculate estimates of the mean number of transfusion days per year. Since EPO 
dose and hematocrit levels were only reported with the administration of ESAs, these analyses were 
restricted to patients who received ESAs at least once during the quarter. Calendar quarter or year was 
treated as a categorical variable in the models to relax the assumption of linearity. The results section 
presents plots of the adjusted estimates for ESA use, EPO dose, transfusion use, number of transfusion 
days, and hemoglobin levels, which are population marginal means that account for changes over time in 
demographic (age, sex, race, ethnicity) and clinical characteristics (primary cause of ESRD, dialysis 
vintage) (189). The trend lines and corresponding 95% confidence intervals were calculated as a 
smoothed conditional mean of the quarterly or yearly adjusted estimates. We stratified estimates by 
cancer site and chemotherapy use, as well as several additional demographic and clinical characteristics. 
We further stratified the analyses by using three categories of cancer site: a) all cancer sites; b) the most 
common solid tumors in our study population (i.e., cancers of the prostate, female breast, colon/rectum, 
lung/bronchus, kidney/renal pelvis, bladder, and pancreas); and c) hematologic malignancies (i.e., 
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 Hodgkin lymphoma, non-Hodgkin lymphoma (NHL), leukemia, and myeloma). We performed complete 
case analyses since covariate missingness was less than 1% (i.e., ethnicity (n=134) and race (n=28)). 
SAS software, version 9.3 (Cary, NC) and RStudio, version 0.98.507 were used to perform analyses 
(207). 
 
 
3. Results 
A total of 39,012 incident cancer patients receiving hemodialysis met eligibility requirements for 
this study. Demographic and clinical characteristics are presented for selected years (i.e., 2000, 2002, 
2004, 2006, 2008, and 2010) in Table 12. The number of eligible patients per year increased from 4,997 
in 2000 to 11,219 in 2010. Over time, patients were more likely to be black, Hispanic, or have diabetes as 
the primary cause of ESRD. Between 2000-2010, mean age at dialysis initiation decreased from 67.9 to 
65.8 years, whereas mean age at cancer diagnosis remained constant. The median duration of dialysis at 
cancer diagnosis was 2.1 years (IQR, 1.3-3.6). The median length of follow-up after cancer diagnosis was 
1.0 year (IQR, 0.3-2.4), and 18.6% of patients remained in follow-up at 3 years post-cancer diagnosis. 
 The distribution of cancer diagnoses by cancer site and year is presented in Figure 11 and 
Supplemental Table 21 (Appendix B). The most frequently diagnosed cancer sites were prostate, 
colorectal, and female breast. Cancers of the kidney/renal pelvis had the most notable increase between 
2000 and 2010, from 6.1% to 10.9% of diagnosed cancers.  
 Over the study period, the quarterly proportion of patients that received ESAs remained relatively 
constant between 92% and 94%. Use of EPO decreased from 94% to 86% between 2002 and mid-2007, 
and then increased to 88% by early 2010. Use of darbepoetin alfa increased from 0% to 8% between 
2002 and mid-2007, and then decreased to 6% by early 2010 (Appendix B, supplemental figure 22). ESA 
use varied by cancer site. Compared to all cancer patients in the study population, patients with common 
solid tumors had similar ESA use whereas patients with hematologic malignancies had lower ESA use 
(figure 12, supplemental figure 23 (Appendix B)). 
Among patients receiving EPO, the mean EPO dose increased from approximately 66,000 
units/month in early 2001 to 83,000 units/month in early 2004, and then declined to 70,000 units/month by 
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 late 2010. Patients with hematologic malignancies used a higher mean EPO dose compared to patients 
with solid tumors (~88,000 vs. 73,000 units/month) (figure 13, supplemental figure 24 (Appendix B)). 
The quarterly proportion of patients that received transfusions increased from 6% in late 2000 to 
9% in late 2010. Use of transfusion was more common among patients with hematologic malignancies 
compared to patients with solid tumors (quarterly mean, 11% vs 8%) (figure 14, supplemental figure 25 
(Appendix B)). Among patients who received transfusion, the mean number of transfusion days per year 
increased steadily from 1.4 to 1.8 days between 2000-2010, with a steeper increase among patients with 
hematologic malignancies (1.5 to 2.4 days) compared to solid tumors (1.5 to 1.7 days) (figure 14). 
Mean quarterly hemoglobin levels followed a similar pattern to EPO dose. Among patients 
receiving ESAs, hemoglobin levels increased from 11.3 g/dL in early 2000 to 11.9 g/dL in late 2006, and 
then declined to 11.2 g/dL in late 2010. Patients with hematologic malignancies had slightly lower mean 
quarterly hemoglobin levels compared to patients with the most common solid tumors (11.5 vs. 11.6 g/dL) 
(figure 15, supplemental figure 26 (Appendix B)). 
The quarterly proportion of chemotherapy receipt decreased from 6.4% in quarter 1 of 2000 to 
4.7% in quarter 4 of 2010. Figure 16 presents quarterly trends in anemia treatment by chemotherapy use. 
Compared to cancer patients who did not receive chemotherapy, patients who received chemotherapy 
had higher mean quarterly ESA use (93% vs. 96%) and higher mean EPO dose (~74,000 vs. 98,000 
units/month). Almost twice as many patients on chemotherapy received quarterly transfusions compared 
to patients who did not receive chemotherapy (15% vs 8%). Mean quarterly hemoglobin levels were lower 
among patients who received chemotherapy compared to patients who did not receive chemotherapy 
(11.4 vs. 11.6 g/dL). 
Analyses stratified by demographic and clinical characteristics revealed several meaningful 
differences in anemia treatment patterns (Appendix B, supplemental figures 27-32). ESA use was lower 
among patients who were male, non-African American, receiving dialysis for <2 years, or with primary 
cause of ESRD due to polycystic kidney disease. EPO dose was lower among patients who were older, 
non-African American, Hispanic, receiving dialysis for <2 years, or with primary cause of ESRD due to 
polycystic kidney disease. Transfusion use was lower among patients who were non-Hispanic, receiving 
77 
 
 dialysis for ≥2 years, or with primary cause of ESRD due to polycystic kidney disease. Hemoglobin levels 
did not vary substantially by subgroups. 
 
 
4. Discussion 
In this national study of anemia treatment patterns among U.S. hemodialysis patients diagnosed 
with incident cancer, we observed extremely high and constant ESA use between 2000 and 2010, even 
during the years of negative safety reports, product labeling changes, black box advisories, revised 
anemia management guidelines, and reimbursement changes. EPO dosing increased until 2004, and 
then declined steadily. Hemoglobin levels followed a similar pattern to EPO dose, with a delayed peak of 
2006. We also observed an increase in the use of transfusions over the study period. This study provides 
novel information on trends in anemia treatment that have not been described in the national dialysis 
population with cancer.  
In contrast to our findings of constant ESA use over time in our hemodialysis population with 
cancer, the oncology literature reports drastic decreases in ESA use (i.e., both EPO and darbepoetin alfa) 
in the years surrounding the 2007 FDA black-box warning. Among VA cancer patients, ESA use 
plateaued in late 2003 and sharply declined from 38% (2006) to 12% (2008) among colon cancer patients 
and from 23% (2006) to 5% (2008) among lung cancer patients (45). Another study of cancer patients 
undergoing chemotherapy across 39 sites in seven states reported a decline from 41% to 30% between 
10-month intervals before and after the 2007 FDA black-box warning (200). Two studies of cancer 
patients treated at MD Anderson Comprehensive Cancer Center reported decreases in ESA use between 
2006 and 2008 of 17% to 5% and 4% to 1% (199, 201). Thus, compared to our hemodialysis population 
with cancer, the oncology population seems to be characterized by higher variability in ESA use by 
calendar year, cancer site, and chemotherapy receipt.  
Although ESA use remained constant among dialysis patients with cancer over the study period, 
we observed an 8% decrease in EPO use between 2002 and 2007 that corresponded with an equivalent 
increase in darbepoetin alfa use. The timing and magnitude of the decline in EPO use follows a pattern 
similar to that previously documented in the hemodialysis population (123). In both studies, EPO use 
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 declined steeply after the emergence of ESA-related safety concerns and continued to decline for years. 
However, the data on darbepoetin alfa use presented in our study suggest that the decline in EPO may 
be due to increased uptake of darbepoetin alfa rather than recent clinical and policy events. It is also 
noteworthy that in our hemodialysis population with cancer we observed slightly lower EPO use and 
hemoglobin levels and slightly higher EPO dosing compared to the larger hemodialysis population. 
Current guidelines conflict regarding appropriate treatment in the subgroup of dialysis patients 
with cancer who do not receive chemotherapy. The guidelines for dialysis patients are similar to the 
guidelines for cancer patients, except the ESA indication for treatment of anemia is restricted to cancer 
patients undergoing myelosuppressive chemotherapy (13, 14). These evidence-based guidelines were 
influenced by studies of cancer patients that consistently reported modification of mortality risk associated 
with ESAs by chemotherapy use (205). As expected, we observed that patients who did not receive 
chemotherapy had higher hemoglobin levels and less intensive anemia treatment, including lower ESA 
use, EPO dose, and transfusion use, compared to patients that received chemotherapy. Yet, the common 
ESA use in this subgroup of patients not receiving myelosuppressive chemotherapy is noteworthy. These 
findings highlight discrepancies between guideline-recommended therapy and actual practice. 
Transfusion avoidance remains an important goal due to dangerous transfusion-related 
complications including hyperkalemia, fluid overload, iron overload and allosensitization (208). Between 
2000 and 2010, we observed an increasing proportion of hemodialysis patients with cancer that received 
transfusions and an increasing mean number of transfusion days per year. Since transfusion avoidance 
provided the formal reason for the original approval and use of ESAs, it seems paradoxical that 
transfusion use is increasing despite constant ESA use (209). One likely explanation for the increase in 
transfusion use is the recent paradigm shift towards lower ESA dosing and lower hemoglobin levels. A 
recent study reported that Medicare hemodialysis patients with 3-month mean hemoglobin levels <10 
g/dL received transfusions at a rate approximately 4 times higher than the rate for patients with 
hemoglobin levels maintained at ≥10 g/dL. Although transfusion rates among patients with hemoglobin 
levels <10 and ≥10 g/dL remained relatively constant between 1999 and 2010, the proportion of patients 
with hemoglobin levels <10 g/dL began to increase after 2006, and consequently, the absolute number of 
patients receiving transfusions also began to increase (203).   
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 Our findings are subject to several limitations. First, our results may not be generalizable to non-
dialysis patients with chronic kidney disease, patients on peritoneal dialysis, patients with a non-Medicare 
primary payer, or patients who died within 9 months of dialysis initiation. Second, claims-based cancer 
definitions have not been validated in the ESRD population. Third, we cannot exclude the possibility of 
misclassifying prevalent cancer cases as incident cases. However, identification of prevalent cancer 
cases during the 6-month baseline period minimized the possibility of misclassification. Fourth, use of 
claims-based definitions made it impossible to determine whether cancers identified as incident cases 
were truly new primaries, metastases, or histories of cancer that were miscoded as new primaries. Fifth, 
we analyzed the number of transfusion days per year rather than the actual number of transfusions, 
because all transfusions administered on any single day are covered by a single procedural code. Sixth, 
ESA claims are provided from outpatient dialysis claims but not from hospital claims. Since ESRD 
patients require several hospital days per year on average, this missing data may yield lower estimates of 
ESA use and dose. Lastly, we may be missing a small proportion of chemotherapy use due to lack of 
access to some specific chemotherapy agent codes (i.e., National Drug Codes). 
Strengths of our study include more than a decade of data on the large and representative 
population of U.S. ESRD patients diagnosed with cancer after hemodialysis initiation. The large sample 
size allowed the novel characterization of anemia management patterns within subgroups, including 
cancer site and chemotherapy use.  
In conclusion, our results suggest that ESA use is extremely common in hemodialysis patients 
with cancer, and robust to recent clinical and policy events driven by safety concerns. The potential risks 
associated with ESA use must be balanced with its known benefits, such as alleviating anemia-related 
symptoms and avoiding transfusion. Although the risks and benefits of ESA use and dosing practices 
have been documented in the dialysis population, little is known about the safety and effectiveness of 
ESA use in the dialysis population with cancer. In addition, the impact of ESA use on health-related 
quality of life needs to be explored in this population. Additional research in the dialysis population with 
cancer is necessary to examine the risk-benefit profile, to understand impact on quality of life, and to 
inform clinical practice.  
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 Table 12. Demographic and clinical characteristics of the study population in 2000, 2002, 2004, 2006, 
2008, and 2010 
 Year 
Characteristics 2000 2002 2004 2006 2008 2010 
Patients (n) 4,997 6,827 8,289 9,620 10,726 11,219 
Age at dialysis initiation 
(years), mean (sd) 
67.9 
(11.7) 
67.4 
(11.7) 
67.4 
(11.9) 
66.8 
(12.3) 
66.4 (12.5) 65.8 
(12.8) 
Age at first cancer 
diagnosis (years), mean 
(sd) 
69.9 
(11.6) 
70.1 
(11.5) 
70.4 
(11.5) 
70.2 
(11.9) 
70.0 (12.0) 69.8 
(12.2) 
Male gender (%) 55.8 56.2 56.2 55.8 56.4 56.0 
Race (%)       
     White 60.9 60.7 60.2 59.1 58.5 57.4 
     Black 35.8 35.9 35.9 36.8 37.7 38.5 
     Asian 1.8 2.1 2.4 2.3 2.3 2.6 
     Native American 0.8 0.8 0.9 0.9 1.0 1.1 
     Other 0.6 0.5 0.6 0.8 0.5 0.4 
     Unknown 0.1 0.0 0.0 0.0 0.0 0.0 
Ethnicity (%)       
     Non-Hispanic 90.7 90.4 89.8 89.0 88.8 88.4 
     Hispanic 8.6 9.1 9.8 10.7 11.0 11.5 
     Unknown 1.0 0.6 0.6 0.4 0.3 0.2 
Reported cause of ESRD 
(%) 
      
     Diabetes 41.0 41.0 40.9 43.2 44.1 44.6 
     Hypertension 34.0 34.5 35.6 34.9 34.6 34.1 
     Glomerulonephritis 10.9 10.5 9.8 9.3 8.8 8.9 
     Polycystic kidney 1.9 1.9 1.9 1.8 1.9 1.8 
     Other 12.3 12.1 11.9 10.9 10.7 10.7 
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 Figure 11. Distribution of cancer diagnoses among U.S. hemodialysis patients with cancer, by first cancer 
site and year, 2000-2010 
 
Other cancers were defined as all other site-specific cancers not listed (e.g., cancers of the esophagus, 
stomach, liver, etc.). Multiple sites indicates patients diagnosed with first cancer at ≥2 sites on the same 
date. 
 
  
82 
 
  Figure 12. Mean quarterly ESA use by cancer site among U.S. hemodialysis patients with cancer, 2000-
2010 
  
a) All cancer sites; b) most common solid tumors in our study population (i.e., cancers of the prostate, 
female breast, colon/rectum, lung/bronchus, kidney/renal pelvis, bladder, and pancreas); and c) 
hematologic malignancies (i.e., Hodgkin lymphoma, non-Hodgkin lymphoma, leukemia, and myeloma). 
Quarterly data points were adjusted for age, sex, race, ethnicity, cause of ESRD, and dialysis vintage. 
Trend lines represent smoothed conditional means. 
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  Figure 13. Mean EPO dose (units/month) by cancer site among U.S. hemodialysis patients with cancer, 
2000-2010 
 
a) All cancer sites; b) most common solid tumors in our study population (i.e., cancers of the prostate, 
female breast, colon/rectum, lung/bronchus, kidney/renal pelvis, bladder, and pancreas); and c) 
hematologic malignancies (i.e., Hodgkin lymphoma, non-Hodgkin lymphoma, leukemia, and myeloma). 
Patients treated at a hospital-based facility were excluded to remove the possibility of simultaneous 
treatment with EPO and darbepoetin alfa. Quarterly data points were adjusted for age, sex, race, 
ethnicity, cause of ESRD, and dialysis vintage. Trend lines represent smoothed conditional means. 
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 Figure 14. Use of blood transfusions by cancer site among U.S. hemodialysis patients with cancer, 2000-
2010 
  
a) Mean quarterly use of blood transfusions and b) mean number of blood transfusion days per year 
among patients who received blood transfusions, by cancer site. Categorical cancer sites were defined as 
1) all cancer sites; 2) most common solid tumors in our study population (i.e., cancers of the prostate, 
female breast, colon/rectum, lung/bronchus, kidney/renal pelvis, bladder, and pancreas); and 3) 
hematologic malignancies (i.e., Hodgkin lymphoma, non-Hodgkin lymphoma, leukemia, and myeloma). 
Data points were adjusted for age, sex, race, ethnicity, cause of ESRD, and dialysis vintage. Trend lines 
represent smoothed conditional means.  
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 Figure 15. Mean quarterly hemoglobin levels by cancer site among U.S. hemodialysis patients with 
cancer, 2000-2010 
 
 
a) All cancer sites; b) most common solid tumors in our study population (i.e., cancers of the prostate, 
female breast, colon/rectum, lung/bronchus, kidney/renal pelvis, bladder, and pancreas); and c) 
hematologic malignancies (i.e., Hodgkin lymphoma, non-Hodgkin lymphoma, leukemia, and myeloma). 
Quarterly data points were adjusted for age, sex, race, ethnicity, cause of ESRD, and dialysis vintage. 
Trend lines represent smoothed conditional means.  
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 Figure 16. Quarterly trends in anemia management by chemotherapy use among U.S. hemodialysis 
patients with cancer, 2000-2010 
 
 
a) Mean ESA use; b) mean EPO dose (units/month); c) mean use of blood transfusions; and d) mean 
hemoglobin levels. Patients treated at a hospital-based facility were excluded from the EPO dose 
calculation to remove the possibility of simultaneous treatment with EPO and darbepoetin alfa. Quarterly 
data points were adjusted for age, sex, race, ethnicity, cause of ESRD, and dialysis vintage. Trend lines 
represent smoothed conditional means. 
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 CHAPTER V.  DISCUSSION 
A. Summary of Findings 
This dissertation research examined the cancer burden among ESRD patients on hemodialysis 
as well as patterns of anemia treatment among ESRD patients on hemodialysis with cancer using 
national data from the Medicare ESRD program. The research had two main objectives: 1) to characterize 
the overall and site-specific cancer burden among ESRD patients without cancer at hemodialysis 
initiation, across demographic and clinical subgroups (Aim 1); and 2) to examine trends in anemia therapy 
in ESRD patients diagnosed with cancer after hemodialysis initiation, for a time period before, during, and 
after ESA-related negative safety reports, product labeling changes, black box advisories, revised anemia 
management guidelines, and reimbursement changes (Aim 2). 
In this large national study of U.S. ESRD patients undergoing hemodialysis, we observed a high 
cumulative incidence of cancer, even after accounting for the substantial competing risk of death in this 
population. Between 1996 and 2009, we observed higher rates of incident cancer diagnoses in the 
dialysis population compared to the U.S. general population, suggesting that ESRD patients are uniquely 
at risk for developing cancer while receiving hemodialysis treatment. Our results demonstrate varying 
patterns of cancer incidence across subgroups, after accounting for measured patient characteristics. 
Among ESRD patients diagnosed with incident cancer after hemodialysis initiation, we observed 
extremely high and constant ESA use between 2000 and 2010 despite safety concerns about ESAs in 
both the ESRD and cancer populations. Even though transfusion avoidance provided the reason for the 
original approval of ESAs, we observed an increasing quarterly proportion of cancer patients who 
received transfusions and an increasing mean number of transfusion days per year. This paradigm shift is 
likely due to the decreasing EPO dose (units/month) and decreasing quarterly hemoglobin levels that we 
observed in the second half of the study period. Both patients with hematological malignancies and 
patients who received chemotherapy had higher ESA use, EPO dose, and transfusion use as well as 
lower hemoglobin levels. Anemia treatment patterns also varied across demographic and clinical 
subgroups.  
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 B.  Public Health Implications 
The results of this dissertation research have several implications for public health and clinical 
practice. First, our estimate of the cumulative incidence of cancer that accounts for the high competing 
risk of death in the dialysis population provides useful information on the total amount of cancer 
diagnoses that will occur in the population. This estimate is valuable for health care policy and planning in 
the dialysis population characterized by very high mortality. Realistic estimates of the cancer burden are 
essential for allocation of resources to cancer prevention, screening, and treatment programs, which is of 
critical importance in the federally funded Medicare population.  
Additionally, the higher cancer incidence documented in certain subgroups of the population 
warrants re-evaluation of cost-effectiveness analyses for cancer screening practices in the dialysis 
population. There are currently no standard recommendations for cancer screening in the dialysis 
population, as previous cost-effectiveness analyses have suggested general cancer screening in this 
population would be a relatively inefficient allocation of financial resources, and would add minimal days 
of life saved per person. However, knowledge of higher cancer risk among subgroups may help to target 
at-risk groups that may benefit from more frequent prevention or screening interventions. 
Finally, understanding temporal trends in anemia therapy among dialysis population with cancer 
is important for a number of reasons. National data on patterns of use of ESAs and blood transfusions 
inform providers about standard practice in the absence of formal guidelines regarding appropriate 
anemia therapy in dialysis patients with cancer. Also, the extremely high and constant ESA use and 
increasing blood transfusion use calls for further research in this population to examine ESA-related 
safety, effectiveness, and impact on health-related quality of life. 
 
 
C. Strengths 
Use of the USRDS data 
We used data from the USRDS which contains inpatient and outpatient information on the large, 
representative population of U.S. ESRD patients on hemodialysis. The large sample size of the 
population allowed characterization of the overall and site-specific cancer burden as well as anemia 
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 treatment within various subgroups, including age, sex, race, ethnicity, primary cause of ESRD, number 
of years on dialysis, and chemotherapy receipt. This dissertation research improves upon existing 
estimates of cancer incidence in the ESRD population which are primarily focused on all cancer sites 
combined or a limited number of cancer sites, and determined from small, select groups of dialysis 
patients. In addition, this research provides the first data on anemia treatment patterns in the dialysis 
population with cancer. 
Exclusion of prevalent cancer cases 
We used a strict definition of incident cancer to avoid bias in our estimates of cancer incidence. 
Although previous studies have consistently excluded patients with a malignancy-related primary cause of 
ESRD from the population at risk, misclassification of prevalent cancer cases has remained a possible 
source of bias. In addition to this exclusion criteria, we required patients to remain cancer-free until 9 
months post-dialysis initiation to prevent misclassifying prevalent cancer cases as incident cases.  
Advanced analytic methods 
The use of advanced analytic approaches improved upon previous work on the cancer burden in 
the dialysis population. First, we estimated 5-year cumulative incidence of overall and site-specific cancer 
accounting for the competing risk of death prior to receipt of a cancer diagnosis. The use of competing 
risks methodology is an innovative approach that is appropriate for the inherent competing risks problem 
in the dialysis population due to the high annual proportion of death. Second, we used inverse probability 
weights to calculate 5-year cumulative incidence estimates stratified by patient characteristics that were 
standardized to the total study sample at baseline with respect to age, sex, race, ethnicity, primary cause 
of ESRD, and calendar year of dialysis initiation. These analytic approaches combined with the rich data 
resource of the USRDS enabled quality estimates of the cancer burden. 
  
 
D. Limitations 
Generalizability of results from USRDS 
The analytic cohorts were restricted by multiple criteria in order to ensure full healthcare 
utilization, capture of relevant claims data, and a homogeneous, cancer-free hemodialysis population at 
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 the start of follow-up. Therefore, our results may not be generalizable to non-dialysis patients with chronic 
kidney disease, patients on peritoneal dialysis, patients with a non-Medicare primary payer, or patients 
who died within 9 months of dialysis initiation. 
Claims-based cancer definitions 
Use of claims-based cancer definitions are both a strength and a limitation of this dissertation 
research. First, claims-based cancer definitions are less stringent than cancer registry data or definitions 
that require pathology reports. Second, validation of site-specific cancer definitions were conducted in the 
Medicare general population rather than the ESRD population. Since ESRD patients likely undergo less 
frequent cancer screening and pursue cancer treatment less aggressively due to high severity of illness 
and shorter life expectancy, the sensitivity and specificity of these claims-based cancer definitions may be 
different in the ESRD population. Third, validation has only been performed for a limited number of cancer 
sites, and the sensitivity varies widely within these sites. Lastly, use of claims-based definitions made it 
impossible to determine whether cancers identified as incident cases were truly new primaries, 
metastases, or histories of cancer that were miscoded as new primaries. 
Misclassification of prevalent cancer cases 
In the absence of pre-dialysis data for the majority of the study population, it is possible that we 
may have misclassified prevalent cancer cases as incident cancer cases, which may result in a slight 
overestimate of cancer incidence. However, unlike previous studies, identification of prevalent cancer 
cases during the 6-month baseline period minimized the possibility of misclassification. 
Misclassification of chemotherapy use 
The USRDS does not include information on a number of variables that could further characterize 
the cancer burden in the ESRD population. These include cancer risk factors such as smoking (e.g., 
cancers of the lung, head/neck, bladder), alcohol (e.g., cancers of the head/neck, esophagus, liver), UV 
radiation (e.g., skin cancer), and family history (e.g., cancers of the breast, colon/rectum, ovary, prostate). 
Cancer stage would also be a useful variable.  
Inability to capture dialysis information from hospitalizations 
Information on ESA use was provided in claims from outpatient dialysis claims but not available 
from hospital claims. Since ESRD patients require several hospital days per year on average, dialysis 
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 administered during hospitalizations would result in missing claims and ultimately yield lower quarterly 
estimates of ESA use and dose.  
Misclassification of chemotherapy use 
For the analysis of patterns of anemia treatment, we stratified the analysis by chemotherapy 
receipt. Any chemotherapy use (yes/no) was ascertained using ICD-9-CM diagnosis and procedure 
codes, Healthcare Common Procedure Coding System (HCPCS) codes, and revenue codes(181, 182). 
Although this approach should capture all chemotherapy use, it is noteworthy that we may be missing a 
small proportion of chemotherapy use due to lack of access to some specific chemotherapy agent codes 
(i.e., National Drug Codes) in the USRDS data.  
 
 
E.  Future Directions 
Future research is warranted to build upon the findings of this dissertation. First, validation of claims-
based cancer definitions using the SEER-Medicare data linkage would be useful for cancer research in 
the ESRD population. Accurate identification of cancer cases remains the major challenge of studying 
cancer in the ESRD population because claims-based cancer definitions have not been validated in the 
ESRD population. Previous validity studies in the elderly general population have evaluated the accuracy 
of cancer diagnoses in Medicare claims data including breast, colorectal, endometrial, lung, pancreatic, 
and prostate cancers as well as leukemia and lymphoma (179, 210-216). However, the validity of claims-
based cancer definitions is likely different in the ESRD population due to higher severity of illness, worse 
functional status, shorter expected lifespan, and more frequent healthcare encounters compared to the 
general population. The SEER-Medicare data linkage, which comprises cancer registry data and 
Medicare claims for inpatient and outpatient services, is uniquely positioned to validate claims-based 
cancer definitions in the ESRD population. Second, a re-evaluation of cancer screening practices in this 
population may be warranted given the updated estimates yielded by this dissertation work. Third, 
additional research is necessary to examine the risk-benefit profile of ESA use in the dialysis population 
with cancer. To date, no studies have been conducted on the safety or effectiveness of ESA use in the 
dialysis population with cancer. For example, ESRD patients with cancer may be at exceptionally high risk 
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 of thrombotic events, which could be explored using this dissertation data set with the addition of 
thrombotic outcome variables derived from Medicare claims data. In addition, the impact of ESA use on 
health-related quality of life ought to be explored in this population. Results from these additional research 
studies would be useful to inform clinical guidelines and practice.  
 
 
F.  Conclusions 
Claims-based cancer definitions identified a high and constant overall burden of cancer among the 
U.S. ESRD population receiving hemodialysis, with certain subgroups of the population exhibiting a 
particularly elevated cancer risk. Despite safety concerns about ESAs in both the ESRD and cancer 
populations, ESA use remained extremely common and constant among hemodialysis patients with 
cancer between 2000 and 2010. In addition, transfusions have increased in frequency despite an effort to 
avoid transfusions due to dangerous health complications. These results warrant additional research to 
examine the risk-benefit profile of ESA use in the dialysis population with cancer. 
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 APPENDICES 
Appendix A. Supplemental analyses for Chapter IV 
 
Figure 17 (Supplemental). Crude annual incidence rates of cancer diagnoses among U.S. hemodialysis 
patients by cancer site, 1996-2009 
 
Other cancers were defined as all other site-specific cancers (e.g., cancers of the esophagus, stomach, 
liver, etc.). The sum of the site-specific cancer rates exceeds the rate for any cancer, due to patients 
diagnosed with multiple cancer sites on the same date.   
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 Figure 18 (Supplemental). Flow diagram of eligibility criteria among U.S. hemodialysis patients 
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 Figure 19 (Supplemental). The crude cumulative incidence of any cancer by time since dialysis initiation, 
accounting for the competing risk of death, by demographic and clinical characteristics 
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Figures were stratified by patient characteristics including (A) age at dialysis initiation; (B) sex; (C) race; 
(D) ethnicity; (E) primary cause of ESRD; (F) year of dialysis initiation; and (G) history of kidney transplant 
evaluation.  
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 Figure 20 (Supplemental). The crude cumulative incidence of any cancer by time since dialysis initiation, 
censoring deaths, by demographic and clinical characteristics 
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Figures were stratified by patient characteristics including (A) age at dialysis initiation; (B) sex; (C) race; 
(D) ethnicity; (E) primary cause of ESRD; (F) year of dialysis initiation; and (G) history of kidney transplant 
evaluation.  
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Figure 21 (Supplemental). Adjusted annual incidence rates of cancer diagnoses by cancer definition 
among U.S. hemodialysis patients, 1996-2009 
  
 
Rates were adjusted for age, sex, race, cause of ESRD, and years on dialysis. Incident cases were 
defined as the first cancer diagnosis of the year among patients without a history of cancer in the last 6 
months of the previous calendar year. 
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Table 13 (Supplemental). Age-, sex-, and race-standardized incidence rates of cancer in the U.S. general 
population, using the U.S. hemodialysis population as the standard, 1996-2009 
Cancer site Standardized incident 
cancer rate per 
100,000 person-years 
(SEER) a 
Unadjusted incident 
cancer rate per 
100,000 person-years 
(USRDS) 
Rate ratio 
All sites b 1464 3874 2.6 
Prostate 604 1209 2.0 
Lung/bronchus 224 548 2.4 
Colon/rectum 173 523 3.0 
Breast (female) 405 778 1.9 
Kidney/renal pelvis 41 419 10.3 
Bladder 70 353 5.1 
NHL 52 231 4.4 
Pancreas 44 169 3.9 
aStandardization was performed using the age, sex, and race distribution of the USRDS study population 
in year 2000 and age-, sex-, and race-specific incident cancer rates in the U.S. population (seer.gov). 
Analysis was limited to whites and blacks due to limited availability of rate estimates for other race in 
SEER general population. 
bThe category for all sites includes all cancer sites diagnosed during the study period, including sites not 
listed in the table (e.g., liver, stomach, esophagus, etc). 
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Table 14 (Supplemental). Demographic and clinical characteristics of 482,510 USRDS patients who 
initiated dialysis between April 1, 1995 and April 5, 2010 
  Person-years at riska 
Characteristics No. (%) of patients Total Mean (SD) 
Calendar period of dialysis initiation    
     1995-1999 127,532 (26.4) 292,669 2.3 (1.5) 
     2000-2004 168,338 (34.9) 392,798 2.3 (1.5) 
     2005-2010 186,640 (38.7) 303,050 1.6 (1.3) 
Age at dialysis initiation (years)    
     18-29 10,739 (2.2) 23,769 2.2 (1.5) 
     30-39 22,278 (4.6) 51,979 2.3 (1.5) 
     40-49 45,694 (9.5) 109,087 2.4 (1.5) 
     50-59 75,599 (15.7) 171,307 2.3 (1.5) 
     60-69 119,906 (24.9) 255,411 2.1 (1.5) 
     70-79 139,490 (28.9) 269,050 1.9 (1.4) 
     ≥80 68,804 (14.3) 107,914 1.6 (1.3) 
Sexb    
     Female 233,597 (48.4) 486,139 2.1 (1.5) 
     Male 248,912 (51.6) 502,376 2.0 (1.5) 
Racec    
     White 302,518 (62.7) 574,321 1.9 (1.4) 
     African American 154,478 (32.0) 357,748 2.3 (1.5) 
     Other 25,357 (5.3) 56,129 2.2 (1.5) 
Ethnicityb, c    
     Hispanic 62,765 (13.1) 139,559 2.2 (1.5) 
     Non-Hispanic 416,901 (86.7) 843,486 2.0 (1.5) 
Reported cause of ESRD    
     Diabetes 243,279 (50.4) 498,067 2.0 (1.5) 
     Hypertension 147,157 (30.5) 299,560 2.2 (1.5) 
     Glomerulonephritis 38,583 (8.0) 83,957 2.2 (1.5) 
History of kidney transplant 
evaluation** 
   
     No 360,602 (74.7) 627,976 1.8 (1.4) 
     Yes 121,908 (25.3) 360,541 2.8 (1.4) 
aPerson-years at risk were calculated from 9 months post-dialysis initiation to the first of the following: the 
event of interest (i.e., first cancer diagnosis); or censoring event (i.e., kidney transplantation; death; end of 
Medicare as primary payer status; change of modality; lost-to-follow-up; 5-years post-dialysis initiation; or 
end of study on December 31, 2010). 
bValues were missing for: sex (n=1), ethnicity (n=1,378). 
cValues were unknown for: race (n=157), ethnicity (n=1,466). 
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Table 15 (Supplemental). The crude 5-year cumulative incidence of less frequent site-specific cancers 
among U.S. hemodialysis patients 
  5-year cumulative incidence % (95% CI) 
Cancer site No. of  
patientsa 
Death treated as  
censoring event 
Death treated as  
competing event 
Lip, oral cavity, and pharynx    
    Lip 110 0.04 (0.03, 0.06) 0.03 (0.02, 0.04) 
    Salivary gland 102 0.04 (0.04, 0.06) 0.03 (0.02, 0.03) 
    Other lip, oral cavity, and pharynx 64 0.03 (0.02, 0.04) 0.02 (0.01, 0.02) 
 
Digestive system    
    Small intestine 148 0.06 (0.05, 0.07) 0.04 (0.03, 0.05) 
    Anus 64 0.03 (0.02, 0.04) 0.02 (0.01, 0.02) 
    Other digestive system 129 0.05 (0.04, 0.06) 0.04 (0.03, 0.04) 
Respiratory system    
    Nasal cavity, middle ear, and 
sinus 
46 0.02 (0.01, 0.03) 0.01 (0.01, 0.02) 
 
    Trachea 26 0.01 (0.01, 0.02) 0.01 (0.01, 0.01) 
    Other respiratory system 74 0.03 (0.02, 0.04) 0.02 (0.02, 0.03) 
Skin/connective tissueb    
    Kaposi sarcoma 68 0.03 (0.02, 0.04) 0.02 (0.01, 0.02) 
Reproductive and genitourinary    
    Breast (male)c 59 0.02 (0.02, 0.03) 0.02 (0.01, 0.02) 
    Placentad 3 -- -- 
    Vagina 37 0.02 (0.01, 0.02) 0.01 (0.01, 0.01) 
    Vulva 90 0.03 (0.03, 0.04) 0.02 (0.02, 0.03) 
    Uterine adnexa, not including 
ovaries 
17 0.01 (0.00, 0.01) 0.00 (0.00, 0.01) 
    Other female genital organsd 2 -- -- 
    Testis 72 0.03 (0.02, 0.04) 0.02 (0.02, 0.02) 
    Penis 67 0.03 (0.03, 0.04) 0.02 (0.02, 0.03) 
    Other male genital organs 12 0.01 (0.00, 0.01) 0.00 (0.00, 0.01) 
    Ureter 44 0.01 (0.01, 0.02) 0.01 (0.01, 0.01) 
    Other urinary system 49 0.02 (0.01, 0.03) 0.01 (0.01, 0.02) 
Neurological    
    Eye 111 0.05 (0.04, 0.06) 0.03 (0.03, 0.04) 
    Mesothelioma 74 0.03 (0.02, 0.04) 0.02 (0.02, 0.03) 
Endocrine    
    Other endocrine glands and 
structures 
146 0.06 (0.05, 0.07) 0.04 (0.03, 0.05) 
Hematological    
    Hodgkin’s disease 135 0.05 (0.04, 0.06) 0.04 (0.03, 0.04) 
Data presented for cancer sites with <150 cases over the study period. Table 10 presents results for 
cancer sites with ≥150 cases. 
a667 patients were diagnosed with multiple cancer sites on the same date. 
bExcludes non-melanoma skin cancer 
cMalignant and carcinoma in situ 
dResults not presented for cancer sites with <5 cases. 
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Table 16 (Supplemental). ICD-9-CM diagnosis codes used to identify site-specific cancer cases from 
Medicare claims 
Cancer site ICD-9 codes 
Lip, oral cavity, and pharynx  
    Lip 140.XX 
    Tongue 141.XX 
    Salivary gland 142.XX 
    Mouth 143.XX-145.XX 
    Pharynx 146.XX-148.XX 
    Other and ill-defined sites within the lip, oral cavity, 
and pharynx 149.XX 
Digestive system  
    Esophagus 150.XX 
    Stomach 151.XX 
    Small intestine 152.XX 
    Colon/rectum 153.XX, 154.0, 154.1, 154.8 
    Anus 154.2, 154.3 
    Liver and intrahepatic bile duct 155.XX 
    Gallbladder and other biliary 156.XX 
    Pancreas 157.XX 
    Other and ill-defined sites within the digestive 
organs and peritoneum 158.XX (except for 158.8),159.XX 
Respiratory system and intrathoracic organs  
    Nasal cavity, middle ear, and sinus 160.XX 
    Larynx 161.XX 
    Lung/bronchus 162.XX (except for 162.0) 
    Trachea 162.0 
    Other and ill-defined sites within the respiratory 
system and intrathoracic organs 163.XX-165.XX (except for 163.9 and 164.1) 
Bone and cartilage 170.XX 
Skin/connective tissue (excludes non-melanoma skin 
cancer)  
    Melanoma 172.XX 
    Connective & other soft tissue 171.XX 
    Kaposi sarcoma 176.XX 
Breast  
    Breast (female), malignant and in situ 174.XX, 233.0 
    Breast (male), malignant and in situ 175.XX, 233.0 
Genitourinary  
    Cervix uteri 180.XX 
    Corpus and uterus 179.XX, 182.XX 
    Placenta 181.XX 
    Ovary 183.0 
    Vagina 184.0 
    Vulva 184.1-184.4 
    Uterine adnexa, not including ovaries 183.2-183.9 
    Other and unspecified female genital organs 184.8-184.9 
    Prostate 185.XX 
    Testis 186.XX 
    Penis 187.1-187.4 
    Other and unspecified male genital organs 187.5-187.9 
    Bladder, malignant & in situ 188.XX, 233.7 
    Kidney and renal pelvis 189.0, 189.1 
    Ureter 189.2 
    Other and unspecified urinary organs 189.3-189.9 
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 Other  
    Eye 190.XX 
    Brain and other nervous system 191.XX-192.XX 
    Mesothelioma 158.8, 163.9, 164.1 
    Thyroid 193.XX 
    Other endocrine glands and structures 194.XX 
Hematological  
    Lymphoma: Hodgkin's disease 201.XX 
    Lymphoma: Non-Hodgkin lymphoma 200.XX, 202.XX excluding 202.4 
    Multiple myeloma 203.0 
    Leukemia 202.4, 204.XX-208.XX 
Ill-defined and unspecified 195.XX-199.XX 
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 Table 17 (Supplemental). Descriptive characteristics of inverse probability of exposure weights by patient 
characteristic 
Characteristic IP of exposure weights 
Mean (minimum, maximum) 
    Age at dialysis initiation 1.001 (0.171, 6.771) 
    Sex 1.000 (0.689, 1.800) 
    Race 1.013 (0.444, 35.804) 
    Ethnicity 1.013 (0.306, 51.936) 
    Reported cause of ESRD 0.999 (0.135, 7.083) 
    Calendar period of dialysis initiation 1.002 (0.676, 2.199) 
    History of kidney transplant evaluation 1.000 (0.549, 25.308) 
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Appendix B. Supplemental analyses for Chapter V 
 
Table 18 (Supplemental). ICD-9-CM diagnosis codes used to identify site-specific cancer cases from 
Medicare claims 
Cancer site ICD-9-CM diagnosis codes 
Lip, oral cavity, and pharynx  
    Lip 140.XX 
    Tongue 141.XX 
    Salivary gland 142.XX 
    Mouth 143.XX-145.XX 
    Pharynx 146.XX-148.XX 
    Other and ill-defined sites within the lip, oral cavity, 
and pharynx 149.XX 
Digestive system  
    Esophagus 150.XX 
    Stomach 151.XX 
    Small intestine 152.XX 
    Colon/rectum 153.XX, 154.0, 154.1, 154.8 
    Anus 154.2, 154.3 
    Liver and intrahepatic bile duct 155.XX 
    Gallbladder and other biliary 156.XX 
    Pancreas 157.XX 
    Other and ill-defined sites within the digestive 
organs and peritoneum 158.XX (except for 158.8),159.XX 
Respiratory system and intrathoracic organs  
    Nasal cavity, middle ear, and sinus 160.XX 
    Larynx 161.XX 
    Lung/bronchus 162.XX (except for 162.0) 
    Trachea 162.0 
    Other and ill-defined sites within the respiratory 
system and intrathoracic organs 163.XX-165.XX (except for 163.9 and 164.1) 
Bone and cartilage 170.XX 
Skin/connective tissue (excludes non-melanoma skin 
cancer)  
    Melanoma 172.XX 
    Connective & other soft tissue 171.XX 
    Kaposi sarcoma 176.XX 
Breast  
    Breast (female), malignant and in situ 174.XX, 233.0 
    Breast (male), malignant and in situ 175.XX, 233.0 
Genitourinary  
    Cervix uteri 180.XX 
    Corpus and uterus 179.XX, 182.XX 
    Placenta 181.XX 
    Ovary 183.0 
    Vagina 184.0 
    Vulva 184.1-184.4 
    Uterine adnexa, not including ovaries 183.2-183.9 
    Other and unspecified female genital organs 184.8-184.9 
    Prostate 185.XX 
    Testis 186.XX 
    Penis 187.1-187.4 
    Other and unspecified male genital organs 187.5-187.9 
    Bladder, malignant & in situ 188.XX, 233.7 
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     Kidney and renal pelvis 189.0, 189.1 
    Ureter 189.2 
    Other and unspecified urinary organs 189.3-189.9 
Other  
    Eye 190.XX 
    Brain and other nervous system 191.XX-192.XX 
    Mesothelioma 158.8, 163.9, 164.1 
    Thyroid 193.XX 
    Other endocrine glands and structures 194.XX 
Hematological  
    Lymphoma: Hodgkin's disease 201.XX 
    Lymphoma: Non-Hodgkin lymphoma 200.XX, 202.XX excluding 202.4 
    Multiple myeloma 203.0 
    Leukemia 202.4, 204.XX-208.XX 
Ill-defined and unspecified 195.XX-199.XX 
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 Table 19 (Supplemental). Administrative codes used to identify anemia treatment 
Anemia treatment Codes 
Epoetin alfa USRDS summarized variables: epo, epoadmin, epodose, n_epo 
Darbepoetin alfa HCPCS: J0880, J0881, J0882, Q0137, Q4054 
Blood transfusions ICD-9-CM procedure codes: 99.03, 99.04 
HCPCS: P9010, P9011, P9016, P9021, P9022, P9038, P9039, 
P9040, 36430 
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Table 20 (Supplemental). Administrative codes used to identify receipt of any chemotherapy from 
Medicare claims 
Medicare claims code type Codes 
ICD-9-CM diagnosis codes V58.1, V66.2, V67.2 
ICD-9-CM procedure codes 99.25 
HCPCS 
964xx, 965xx, C1167, C9127, C9205, C9213, C9214, C9215, 
C9257, C9414, C9415, C9418, C9420, C9421,C9425, C9427, 
C9431, C9432, C9440, J8520, J8521, J8530, J8560, J8565, J8610, 
J9000-J9999, G0355-G0362 (for 2005 only), Q0083-Q0085, Q2024, 
S0116, S1016 
Revenue center codes 0331, 0332, 0335 
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Table 21 (Supplemental). Distribution of site-specific cancer cases among study population by year, 2000-2010 
Cancer Site 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 
    Breast (female) 513 627 720 802 876 975 995 1062 1115 1176 1177 
    Colon/rectum 627 762 840 912 1027 1083 1081 1191 1209 1205 1241 
    Kidney/renal pelvis 305 414 455 531 657 761 861 997 1066 1152 1218 
    Leukemia 123 161 181 198 201 212 252 251 272 292 298 
    Lung/bronchus 497 607 695 759 797 844 890 889 947 931 954 
    Hodgkin lymphoma 12 10 14 25 29 35 38 36 36 47 41 
    Myeloma 149 163 195 204 217 243 238 233 270 284 269 
    NHL 142 186 194 203 231 279 311 342 384 381 377 
    Pancreas 85 107 125 109 132 146 180 164 178 186 205 
    Prostate 859 1048 1164 1277 1401 1496 1620 1687 1783 1882 1864 
    Bladder 263 362 404 440 515 541 559 596 611 606 590 
    Other** 1,273 1,475 1,659 1,792 1,958 2,159 2,319 2,387 2,522 2,621 2,620 
    Multiple sites*** 149 165 181 217 248 260 276 301 333 343 365 
Total (including patients with 
missing race/ethnicity 
information) 4,997 6,087 6,827 7,469 8,289 9,034 9,620 10,136 10,726 11,106 11,219 
Total patients missing 
race/ethnicity 19 17 14 9 16 15 16 14 13 15 14 
Total (excluding patients 
with missing race/ethnicity 
information) 4,978 6,070 6,813 7,460 8,273 9,019 9,604 10,122 10,713 11,091 11,205 
*Cancer cases may be included in multiple years.  
**Other cancers were defined as all other site-specific cancers not listed (e.g., cancers of the esophagus, stomach, liver, etc).  
***Multiple sites indicates patients diagnosed with first cancer at ≥2 sites on the same date. 
 
 Figure 22 (Supplemental). Mean quarterly ESA use by drug type among U.S. hemodialysis patients with 
cancer, 2000-2010 
  
Quarterly data points were adjusted for age, sex, race, ethnicity, cause of ESRD, and dialysis vintage. 
Trend lines represent smoothed conditional means. 
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Figure 23 (Supplemental). Mean ESA use by cancer site among U.S. hemodialysis patients with cancer, 
2000-2010 
  
a) Common solid tumors; and b) hematologic malignancies. Hodgkin lymphoma was not presented due to 
small sample size. Quarterly data points were adjusted for age, sex, race, ethnicity, cause of ESRD, and 
dialysis vintage. Trend lines represent smoothed conditional means. 
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Figure 24 (Supplemental). Mean EPO dose (units/month) by cancer site among U.S. hemodialysis 
patients with cancer, 2000-2010 
 
a) Common solid tumors; and b) hematologic malignancies. Hodgkin lymphoma was not presented due to 
small sample size. Patients treated at a hospital-based facility were excluded to remove the possibility of 
simultaneous treatment with EPO and darbepoetin alfa. Quarterly data points were adjusted for age, sex, 
race, ethnicity, cause of ESRD, and dialysis vintage. Trend lines represent smoothed conditional means.  
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 Figure 25 (Supplemental). Mean use of blood transfusions by cancer site among U.S. hemodialysis 
patients with cancer, 2000-2010 
 
a) Common solid tumors; and b) hematologic malignancies. Hodgkin lymphoma was not presented due to 
small sample size. Quarterly data points were adjusted for age, sex, race, ethnicity, cause of ESRD, and 
dialysis vintage. Trend lines represent smoothed conditional means. 
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 Figure 26 (Supplemental). Mean quarterly hemoglobin levels by cancer site among U.S. hemodialysis 
patients with cancer, 2000-2010 
 
 
 
a) Common solid tumors; and b) hematologic malignancies. Hodgkin lymphoma was not presented due to 
small sample size. Quarterly data points were adjusted for age, sex, race, ethnicity, cause of ESRD, and 
dialysis vintage. Trend lines represent smoothed conditional means. 
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 Figure 27 (Supplemental). Quarterly trends in anemia management by age among U.S. hemodialysis 
patients with cancer, 2000-2010 
 
 
a) Mean ESA use; b) mean EPO dose (units/month); c) mean use of blood transfusions; and d) mean 
hemoglobin levels. Patients treated at a hospital-based facility were excluded from the EPO dose 
calculation to remove the possibility of simultaneous treatment with EPO and darbepoetin alfa. Quarterly 
data points were adjusted for age, sex, race, ethnicity, cause of ESRD, and dialysis vintage. Trend lines 
represent smoothed conditional means. 
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 Figure 28 (Supplemental). Quarterly trends in anemia management by sex among U.S. hemodialysis 
patients with cancer, 2000-2010 
 
 
 
a) Mean ESA use; b) mean EPO dose (units/month); c) mean use of blood transfusions; and d) mean 
hemoglobin levels. Patients treated at a hospital-based facility were excluded from the EPO dose 
calculation to remove the possibility of simultaneous treatment with EPO and darbepoetin alfa. Quarterly 
data points were adjusted for age, sex, race, ethnicity, cause of ESRD, and dialysis vintage. Trend lines 
represent smoothed conditional means. 
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 Figure 29 (Supplemental). Quarterly trends in anemia management by race among U.S. hemodialysis 
patients with cancer, 2000-2010 
 
 
a) Mean ESA use; b) mean EPO dose (units/month); c) mean use of blood transfusions; and d) mean 
hemoglobin levels. Patients treated at a hospital-based facility were excluded from the EPO dose 
calculation to remove the possibility of simultaneous treatment with EPO and darbepoetin alfa. Quarterly 
data points were adjusted for age, sex, race, ethnicity, cause of ESRD, and dialysis vintage. Trend lines 
represent smoothed conditional means. 
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Figure 30 (Supplemental). Quarterly trends in anemia management by ethnicity among U.S. hemodialysis 
patients with cancer, 2000-2010 
 
 
a) Mean ESA use; b) mean EPO dose (units/month); c) mean use of blood transfusions; and d) mean 
hemoglobin levels. Patients treated at a hospital-based facility were excluded from the EPO dose 
calculation to remove the possibility of simultaneous treatment with EPO and darbepoetin alfa. Quarterly 
data points were adjusted for age, sex, race, ethnicity, cause of ESRD, and dialysis vintage. Trend lines 
represent smoothed conditional means. 
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Figure 31 (Supplemental). Quarterly trends in anemia management by primary cause of ESRD among 
U.S. hemodialysis patients with cancer, 2000-2010 
 
 
a) Mean ESA use; b) mean EPO dose (units/month); c) mean use of blood transfusions; and d) mean 
hemoglobin levels. Patients treated at a hospital-based facility were excluded from the EPO dose 
calculation to remove the possibility of simultaneous treatment with EPO and darbepoetin alfa. Quarterly 
data points were adjusted for age, sex, race, ethnicity, cause of ESRD, and dialysis vintage. Trend lines 
represent smoothed conditional means. 
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 Figure 32 (Supplemental). Quarterly trends in anemia management by dialysis vintage among U.S. 
hemodialysis patients with cancer, 2000-2010 
 
 
 
a) Mean ESA use; b) mean EPO dose (units/month); c) mean use of blood transfusions; and d) mean 
hemoglobin levels. Patients treated at a hospital-based facility were excluded from the EPO dose 
calculation to remove the possibility of simultaneous treatment with EPO and darbepoetin alfa. Quarterly 
data points were adjusted for age, sex, race, ethnicity, cause of ESRD, and dialysis vintage. Trend lines 
represent smoothed conditional means. 
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